<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Public Health</journal-id>
<journal-title>Frontiers in Public Health</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Public Health</abbrev-journal-title>
<issn pub-type="epub">2296-2565</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fpubh.2022.878161</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Public Health</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Human Adenovirus Associated Hepatic Injury</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Zheng</surname> <given-names>Nan</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1748153/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname> <given-names>Yan</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1711286/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Rong</surname> <given-names>Hechen</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1526696/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname> <given-names>Kun</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1748191/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Huang</surname> <given-names>Xiaoping</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1075877/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Infectious Diseases, First Affiliated Hospital of Soochow University</institution>, <addr-line>Suzhou</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Gastroenterology, First Affiliated Hospital of Soochow University</institution>, <addr-line>Suzhou</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Wenyu Lin, Massachusetts General Hospital and Harvard Medical School, United States</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Zhiliang Hu, Nanjing Second Hospital, China; Tuo Shao, Massachusetts General Hospital and Harvard Medical School, United States</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Xiaoping Huang <email>grehxp&#x00040;163.com</email></corresp>
<fn fn-type="other" id="fn001"><p>This article was submitted to Infectious Diseases &#x02013; Surveillance, Prevention and Treatment, a section of the journal Frontiers in Public Health</p></fn></author-notes>
<pub-date pub-type="epub">
<day>28</day>
<month>04</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>10</volume>
<elocation-id>878161</elocation-id>
<history>
<date date-type="received">
<day>17</day>
<month>02</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>03</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2022 Zheng, Wang, Rong, Wang and Huang.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Zheng, Wang, Rong, Wang and Huang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p>Human adenovirus (HAdV) is a common virus, but the infections it causes are relatively uncommon. At the same time, the methods for the detection of HAdV are varied, among which viral culture is still the gold standard. HAdV infection is usually self-limited but can also cause clinically symptomatic in lots of organs and tissues, of which human adenovirus pneumonia is the most common. In contrast, human adenovirus hepatitis is rarely reported. However, HAdV hepatitis has a high fatality rate once it occurs, especially in immunocompromised patients. Although human adenovirus hepatitis has some pathological and imaging features, its clinical symptoms are not typical. Therefore, HAdV hepatitis is not easy to be found in the clinic. There are kinds of treatments to treat this disease, but few are absolutely effective. In view of the above reasons, HAdV hepatitis is a disease that is difficult to be found in time. We reviewed and summarized the previously reported cases, hoping to bring some relatively common characteristics to clinicians, so as to facilitate early detection, early diagnosis, and early treatment of patients.</p></abstract>
<kwd-group>
<kwd>human adenovirus</kwd>
<kwd>hepatitis</kwd>
<kwd>pathogenesis</kwd>
<kwd>pathology</kwd>
<kwd>therapy</kwd>
</kwd-group>
<contract-num rid="cn001">31010303010946</contract-num>
<contract-sponsor id="cn001">Chinese Foundation for Hepatitis Prevention and Control<named-content content-type="fundref-id">10.13039/501100005198</named-content></contract-sponsor>
<counts>
<fig-count count="0"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="98"/>
<page-count count="11"/>
<word-count count="10060"/>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>Introduction</title>
<p>Human adenoviruses (HAdVs), the widespread pathogens of the Adenoviridae family, are non-enveloped, double-stranded deoxyribonucleic acid (DNA) viruses. About 60 years earlier, HAdV had been independently discovered by Rowe et al. and written by Hilleman et al. (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>).</p>
<p>Human adenovirus possesses a similar icosahedral capsid with a diameter of approximately 90 nm and contains the trimeric fibrin with variable length (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>). The capsid is wrapped in a tightly packed viral protein and DNA genome (between 34 and 37 kbp), known as core (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>). HAdV is divided into serotypes (1&#x02013;104) together with single species (A-G) (<xref ref-type="table" rid="T1">Table 1</xref>; <ext-link ext-link-type="uri" xlink:href="http://hadvwg.gmu.edu/">http://hadvwg.gmu.edu/</ext-link>) through conventional serotype, viral DNA restriction enzyme digestion, sequencing, and the serotype-specific PCR.</p>
<table-wrap position="float" id="T1">
<label>Table 1</label>
<caption><p>Current spectrum of known HAdVs.</p></caption>
<table frame="hsides" rules="groups">
<tbody><tr>
<td valign="top" align="left">A</td>
<td valign="top" align="center">12, 18, 31, 61</td>
</tr>
<tr>
<td valign="top" align="left">B</td>
<td valign="top" align="center">3, 7, 11, 14, 16, 21, 34, 35, 50, 55, 66, 68, 76&#x02013;79</td>
</tr>
<tr>
<td valign="top" align="left">C</td>
<td valign="top" align="center">1, 2, 5, 6, 57, 89, 104</td>
</tr>
<tr>
<td valign="top" align="left">D</td>
<td valign="top" align="center">8&#x02013;10, 13, 15, 17, 19, 20, 22&#x02013;30, 32, 33, 36&#x02013;39, 42&#x02013;49, 51, 53, 54, 56, 58, 59, 60, 63, 64, 65, 67, 69&#x02013;75, 80&#x02013;88, 90&#x02013;103</td>
</tr>
<tr>
<td valign="top" align="left">E</td>
<td valign="top" align="center">4</td>
</tr>
<tr>
<td valign="top" align="left">F</td>
<td valign="top" align="center">40, 41</td>
</tr>
<tr>
<td valign="top" align="left">G</td>
<td valign="top" align="center">52</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>The HAdV species (A-G) and types (104) belonging to individual species are indicated</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>In immunocompetent individuals, HAdV infection usually causes upper respiratory, gastrointestinal (GI), or conjunctival involvement. The vast majority of cases are self-restricting, while in the immunocompetent hosts, fatal and disseminated infections are rare. HAdV can sometimes result in serious infections in the immunocompromised individuals, for example, hemorrhagic cystitis, gastroenteritis, pneumonia, encephalitis, nephritis, enterocolitis, hepatitis, or the disseminated diseases, leading to the evident incidence rate and mortality. Some serotypes can lead to more seeking infections, even to the death of immunodeficient infants and patients. For instance, HAdV7, HAdV5, and HAdV3 are the causes of acute respiratory infections, and the recently, the outbreak of HAdV7 at the rehabilitation center of New Jersey caused 11 deaths (<ext-link ext-link-type="uri" xlink:href="https://www.nj.gov/health/cd/topics/adenovirus.shtml">https://www.nj.gov/health/cd/topics/adenovirus.shtml</ext-link>), whereas HAdV41 and HAdV40 are known to result in persistent and acute gastroenteritis in children (<xref ref-type="bibr" rid="B7">7</xref>).</p>
<p>On account of their genetic heterogeneity, HAdV species have very diverse tropism, leading to the infection of various tissues and organs. Some of HAdV species E and D (HAdV-D) mainly result in keratoconjunctivitis (EKC) (<xref ref-type="bibr" rid="B8">8</xref>), the infections of HAdV-C, B, and A can cause GI, respiratory, and urinary diseases, and the GI disease is also resulted from HAdV-E and F (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>). Subgroup D adenovirus serotype is known for its tendency to the eye, leading to epidemic EKC or conjunctivitis (<xref ref-type="bibr" rid="B11">11</xref>). Hepatitis is mainly correlated with subgroup C serotypes (HAdV 5, 2, and 1), especially serotype 5 infection is related to the occurrence of hepatitis in liver transplant recipients (<xref ref-type="bibr" rid="B12">12</xref>). In the following, we will review HAdV and HAdV hepatitis.</p>
</sec>
<sec id="s2">
<title>Epidemiology of HAdV</title>
<p>Adenovirus infection can be resulted from latent virus reactivation or contact with the infected individuals. Adenovirus can be transmitted by the inhalation of infected aerosols, person-to-person contact, fecal-oral route, direct conjunctival inoculation, or contact with infected blood or tissue. Infections occur at any time of the year without apparent seasonal (<xref ref-type="bibr" rid="B12">12</xref>), despite the great majority of epidemics occurs in early spring or winter (<xref ref-type="bibr" rid="B13">13</xref>). In the meanwhile, HAdV has a worldwide distribution. The regional or local epidemics are described, but many infections occur as sporadic events. HAdV is resistant to numerous disinfectants; however, ethanol solution (95%) is a useful disinfectant (<xref ref-type="bibr" rid="B14">14</xref>).</p>
<p>Adenovirus infections are most common in the healthy children (especially children under 4 years) (<xref ref-type="bibr" rid="B15">15</xref>), adults in the closed environment (such as military and college), and immunocompromised patients. In immunocompetent people, HAdV make up exceed 50% of pneumonia cases and febrile respiratory illness (FRI) among the unvaccinated recruits, in the United States, simultaneously globally (<xref ref-type="bibr" rid="B16">16</xref>).</p>
<p>In immunocompromised patients, adenovirus infections are almost described in the recipients of solid organ transplantation (SOT) together with hematopoietic stem cell transplant (HSCT). In patients with human immunodeficiency virus (HIV) infection, the incidence of HAdV infection is between 12 and 28%. Among the recipients of HSCT, for the HAdV infection, its incidence is between 3 and 47%. Available data indicate that the incidence rate of allogeneic (from 5 to 47%) HSCT receptor is much greater than that of the autologous HSCT receptor (between 2.5 and 14%) (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>). Furthermore, the studies have shown that the adenoviral infections are more prevalent in the patients containing acute graft-versus-host disease (GVHD), severe T-cell depletion, cord-blood donors, human leukocyte antigen (HLA) mismatch, and patients who use of alemtuzumab (<xref ref-type="bibr" rid="B10">10</xref>). In addition, a wide variety of SOT populations have been reported to be infected with adenovirus, including those receiving liver, renal, heart, intestinal, and lung transplants. The HAdV infection incidence in the recipients of SOT is between 5 and 22%, generally within the first 6 months after the transplantation. For the adenovirus infection, its risk factors in the recipients of SOT contain liver transplant and small bowel recipients, patients receiving anti-lymphocyte antibodies, child transplant recipients, and patients with recipient negative or donor positive adenovirus status (<xref ref-type="bibr" rid="B19">19</xref>).</p>
<p>The incubation period of HAdV infection is determined by the transmission mechanism and virus serotype, between a few days and more than a week. In patients with normal immune function, the viral shedding from throat of patients with common cold will fall off for about 1&#x02013;3 days; the virus shedding from throat, nose, eyes, or stool of patients with pharyngeal conjunctival fever were for 3&#x02013;5 days; the virus shedding from corneal conjunctivitis eyes were for 2 weeks; the virus shedding from stool or throat of children with systemic or respiratory diseases were for 3&#x02013;6 weeks. Despite the details of virus shedding in the immunocompromised patients are restricted, the shedding time is generally longer. The proposed positions of viral latency contain the intestine, pharynx (adenoids and tonsils), lymphocytes, and urinary tract, despite some of them are still controversial (<xref ref-type="bibr" rid="B20">20</xref>).</p>
</sec>
<sec id="s3">
<title>High-Risk Factors of HAdV Hepatitis</title>
<p>Hepatitis can be caused by a variety of causes. If not treated, it can lead to liver transplantation, death, or acute liver failure (ALF). Possible causes of hepatitis contain drugs, autoimmune hepatitis, toxins, venous obstruction, ischemia, and metabolic together with infectious causes, containing cytomegalovirus (CMV), varicella zoster virus (VZV), hepatitis A to E, Epstein&#x02013;Barr virus (EBV), herpes simplex virus (HSV), and human adenovirus. Although human adenovirus (HAdV) hepatitis was rarely been reported, HAdV hepatitis can occur in immunocompromised patients. First of all, we will mainly introduce the high-risk factors of HAdV hepatitis.</p>
<p>In a recent study, 66% of the patients were patients with pediatrics. This observation is very consistent with the outcomes of a recent meta-analysis, which found that 64% of cases of HAdV hepatitis occurred in children (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>). In the pediatric setting, the most prevalent predisposing condition may be liver transplantation. In the meantime, children may also develop HAdV hepatitis in the process of immunosuppression after the transplantation of hematopoietic stem cell, chemotherapy for solid malignancies or lymphoblastic leukemia, and severe combined immunodeficiency (SCID) (<xref ref-type="bibr" rid="B23">23</xref>).</p>
<p>However, some studies have shown that the proportion of HAdV hepatitis in adult patients who are immunosuppressed after the transplantation of hematopoietic stem cell is higher than that in adult patients after liver transplantation (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>). Adults are probably developed HAdV hepatitis when SOT other than the liver or chemotherapy leads to immunosuppression (<xref ref-type="bibr" rid="B26">26</xref>). All in all, in SOT recipients, most reported cases of HAdV hepatitis appeared in the recipients of liver transplant. What is more, it was reported that one patient was just given chemotherapy about a year prior to the HAdV infection. Despite he was not immunosuppressed actively, his residual lymphoplasmacytic lymphoma was found to involve kidney, spleen, and bone marrow at the autopsy, and HAdV infection was discovered in his liver. It is well known that lymphoma may cause a certain degree of immunosuppression (<xref ref-type="bibr" rid="B27">27</xref>). The study suggests that the immunosuppression degree resulted from lymphoma is probably enough to cause patients to develop the fatal HAdV hepatitis (<xref ref-type="bibr" rid="B22">22</xref>).</p>
<p>In conclusion, most risk factors for HAdV hepatitis include SOT, human immunodeficiency virus infection, chemotherapy, the transplantation of hematopoietic stem cell, SCID, and lymphoma (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B28">28</xref>).</p>
</sec>
<sec id="s4">
<title>Pathogenesis of HAdV Hepatitis</title>
<p>Despite the human adenoviral hepatitis has been reported before, it mainly appears in the manner of small series and individual case reports and does not always emphasize the pathogenesis. The infection of human adenovirus rarely leads to serious pathological changes; however, the intravenous injection of high-dose replication-deficient HAdV vector into the body of patients will lead to rapid innate immune system activation, resulting in disseminated intravascular coagulation, cytokine storm syndrome, hepatotoxicity, and thrombocytopenia. Meanwhile, HAdV-C5 vectors have high hepatic tropism, and the intravascular administration of HAdV-C5 vectors can result in acute liver toxicity. So, the pathogenesis of hepatitis caused by HAdV-C5 vectors can be partly represented the hepatitis caused by HAdV.</p>
<p>In the article of Alemany et al., after intravenous virus administration, virus particles can be isolated in endothelial cells of splenic sinuses and liver, tissue macrophages, and platelets <italic>via</italic> directly binding to the receptors of cell surface (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B30">30</xref>). In addition, tissue resident macrophages in the liver, for instance, Kupffer cells, can also isolate a large number of HAdV particles (<xref ref-type="bibr" rid="B31">31</xref>&#x02013;<xref ref-type="bibr" rid="B33">33</xref>). Coagulation factors that contain Gla domain can mediate the entry of virus into hepatocytes through binding to the main viral capsid protein hexon (<xref ref-type="bibr" rid="B34">34</xref>). These coagulation factors contain FX, FIX, and FVI, and FX has the highest affinity with the HAdV-C5 hexon (<xref ref-type="bibr" rid="B35">35</xref>). It had been proven that protein associated with LDL receptor and heparan sulfate proteoglycan (HSPG) can mediate the cell entry of the coagulation factor HAdV-C5 complexes existed <italic>in vitro</italic> (<xref ref-type="bibr" rid="B36">36</xref>). Nevertheless, macrophages residing in the tissues are only the first line of defense against the invading pathogens, and the activation of innate immune system sensors was triggered by these cells. Then, 10 min after the HAdV-C5 intravenous injection, in the liver, the Kupffer cells activated the transcription of proinflammatory cytokine IL-1a (<xref ref-type="bibr" rid="B33">33</xref>). Subsequently, IL-1a is synthesized continuously, which triggers the generation of pro-inflammatory cytokines depended on IL-1RI, containing TNF-a and IL-6, as well as chemokines CXCL2, CXCL1, and CCL2 (<xref ref-type="bibr" rid="B33">33</xref>). Then, IL-1a is constantly being synthesized and triggers the generation of pro-inflammatory cytokines depended on IL-1RI, containing TNF-a and IL-6, as well as chemokines CXCL2, CXCL1, and CCL2 (<xref ref-type="bibr" rid="B33">33</xref>). In the meantime, after the isolation of HAdV from blood, Kupffer cells undergo necrotic death within 60 min after intravenous injection of HAdV. For the death of necrotic Kupffer cell, the result is the activation of systemic inflammatory response, resulting in the release of pre-synthesized cytosolic IL-1a together with other proinflammatory mediators, containing HMGB1, in circulation (<xref ref-type="bibr" rid="B37">37</xref>). When necrotic cells are released, systemic and local IL-1RI signals are initiated by IL-1a (<xref ref-type="bibr" rid="B38">38</xref>). Thus, IL-1a activation can also cause severe immunopathology of the infected liver.</p>
<p>The cells of natural killer (NK) existed in a liver-directed gene transfer mouse model were found to play a major role in eliminating hepatocytes infected with the HAdV-C5-based vector (<xref ref-type="bibr" rid="B39">39</xref>). Within 3 days after the intravenous injection of vector, NK cells existed in the spleen were activated highly and expressed IFN-c, glutamate B, and perforin. Besides, in the cells of NK, the expression of the cytotoxic effectors is completely determined by the functional IFN-I signal. The research has suggested that on account of the lack of IFN-I signal, there is a cell population dysfunction of NK and the prolonged duration of transgenic hepatocytes infected by virus. Therefore, the removal of virus infected cells from liver is principally mediated <italic>via</italic> the activated cells of NK. The same research exhibits that viral infection cell lysis mediated by NK cell requires the main NK cell activation receptor NKG2D (<xref ref-type="bibr" rid="B40">40</xref>). NK cells mediate antiviral innate immune responses by producing cytokines and dissolving infected cells when activated (<xref ref-type="bibr" rid="B41">41</xref>&#x02013;<xref ref-type="bibr" rid="B43">43</xref>). Activated NK cells help to control the early stage of infection and promote the in-depth initiation for the virus-specific immunity of CD8&#x0002B; T-cell. In one study, the aggravation of hepatocellular damage observed during human adenovirus infection associated with a raising expression of IFN-&#x003B3; and the CD8&#x0002B; T-cell absolute numbers in liver (<xref ref-type="bibr" rid="B44">44</xref>). This is in accordance with other liver infection models, where the emergence of hepatocyte injury is related to the obtainment of the effector function <italic>via</italic> CD8&#x0002B; T-cells (<xref ref-type="bibr" rid="B45">45</xref>).</p>
<p>Combined with the previous studies, the indirect effect related to immune damage is more important than direct effect of viral infection. As a recent study shows that disseminated infections caused by HAdV-C in immunocompromised hosts are known to trigger severe acute inflammatory responses, which are manifest in part by high blood levels of inflammatory cytokines and chemokines, such as IL-1, IL-6, TNF-<bold>&#x003B1;</bold>, IFN-a/b, IFN-c, and IL-8 (<xref ref-type="bibr" rid="B46">46</xref>). While promoting virus-infected cells to be cleared from the body, these inflammatory cytokines and chemokines aggravate virus-induced inflammation, severe immune pathology, and damage to healthy tissues, leading to multiple organ dysfunction and even death. In addition, Fejer et al. have shown that intravenous or intraperitoneal administration of HAdV-C2 or HAdV-C5 leads to the development of hypersensitivity to secondary challenge of mice with lipopolysaccharide (LPS) (<xref ref-type="bibr" rid="B47">47</xref>).</p>
</sec>
<sec id="s5">
<title>Pathological Features of HAdV Hepatitis</title>
<p>Histopathological assessment is the gold standard for diagnosing the HAdV hepatitis. When tissues are infected with human adenovirus, routine examination of eosin-stained and hematoxylin slides can exhibit different degrees of regeneration, reactivity, and inflammation. By <italic>in situ</italic> and immunoperoxidase hybridization, we can confirm the presence of the virus in tissues (such as liver) (<xref ref-type="bibr" rid="B19">19</xref>). Human adenovirus-infected cells (which known as &#x0201C;smudge cells&#x0201D;) are a typical type of the intranuclear inclusions containing thin cytoplasmic margins and large nuclei, basophilic inclusions.</p>
<p>Recently, the research exhibited twelve human adenoviral hepatitis cases, containing autopsy specimens and biopsy (<xref ref-type="bibr" rid="B22">22</xref>). All of the above cases possessed histological evidence of liver injury and laboratory or immunohistochemical (IHC) evidence of the infection of active human adenovirus (e.g., electron microscopy, polymerase chain reaction (PCR), virus culture, and other additional approaches). The two pathologists review all of the cases (KBS and JPTH), and all the cases were discussed and agreed. They examined various morphological findings, containing granulomatous inflammation, varying degrees of necrosis, and the existence of inclusion bodies, lymphocytes, and neutrophils.</p>
<p>In this paper, tissue sections of all the cases revealed non-banded coagulative hepatocyte necrosis, and necrosis was divided into spotty hepatocyte necrosis, submassive necrosis, and massive necrosis, with a corresponding percentage of necrosis ranging from &#x0003C;5 to 95%. Punctate hepatocyte necrosis was employed for expressing the apoptosis or necrosis of isolated hepatocytes in lobules, whereas massive necrosis referred to extensive necrosis of nearly all or all normal liver lobules. The submassive necrosis was applied for expressing a moderate number of necrosis, generally manifested as confluent necrotic region. Despite this necrosis is generally completely non-banded, half of the cases confirmed raised involvement in the periportal area on the biopsy specimens. On the contrary, autopsy revealed complete non-banded necrosis. The change from extreme punctate, focal necrosis to massive, and wide necrosis seems to be determined by the progression and timing of HAdV infection as well as sampling. Notably, the percentage of necrosis in this small biopsy sample is probably underlying misleading on account of the restrictions of sampling and the liver heterogeneous involvement. Histological variations revealed that there exists some anatomical heterogeneity in liver. In a case, despite peripheral liver biopsy revealed only rare granuloma and focal portal vein lymphocyte infiltration, the biopsy of discrete liver lesions guided by simultaneous image observed <italic>via</italic> abdominal MRI and CT exhibited a large number of intranuclear inclusions and necrosis. A total of 33% of the patients with imaging reports provided for review suggested heterogeneous or focal imaging outcomes. Necrosis will also progress as the progresses of disease. The comparison of autopsy specimen and biopsy specimen patients indicated that the percentage of necrosis raised from 20 to 60% from the initial biopsy time.</p>
<p>In all cases in this paper, characteristic stains in hepatocytes to inclusion bodies in vitreous nuclei were reflected in tissue sections. These inclusions are most prevalent at the edge of the necrotic region, however, sometimes scattered in lobules. Despite these inclusions are nearly basophilic, a few cases suggest that the inclusions have glassy eosinophilic regions. Well-developed and particularly large inclusion bodies usually possess a central eosinophilic glassy appearance, and basophilic chromatin is marginalized. Besides, in a case (8%; 1/12), inclusion bodies were also found in the bile duct epithelium. Adenoviral ascending biliary hepatitis has formerly been reported to be associated with the GI infection existed in the immunosuppressed children, which may be the outcome of GI ascending infection entering biliary tract (<xref ref-type="bibr" rid="B48">48</xref>). Nonetheless, there was few related inflammations in most cases (58%, 7/12). If exists, inflammation is lymphoid and focal, while no neutrophilic inflammation was identified.</p>
</sec>
<sec id="s6">
<title>Imaging Characteristic of HAdV Hepatitis</title>
<p>Although the imaging characteristics of HAdV hepatitis are often non-specific, radiology plays a more essential role in the suspected patients with HAdV hepatitis, it is conducive to exclude other causes. Non-specific images of magnetic resonance imaging and computed tomography revealed periportal edema and liver enlargement. The clear low attenuation regions and uneven enhancement existed on the CT, whereas periportal edema possessed high signal intensity regions on MRI T2-weighted images (<xref ref-type="bibr" rid="B49">49</xref>). Among some patients with HAdV hepatitis, we can also find multiple hypodense lesions or single hypodense lesion in CT.</p>
<p>In one case, a biopsy guided by simultaneous image of a liver lesion revealed massive necrosis, while the lesion was thought to represent an abscess when it was first found on a CT scan of the abdomen because of the lesion with an intrahepatic rim-enhancing (<xref ref-type="bibr" rid="B22">22</xref>). In the same study, a patient&#x00027;s lesion was mistaken for cirrhosis by ultrasound because of the heterogeneously necrotic appearance of the liver. Another patient was explicated <italic>via</italic> CT scan as a lymphoma involving the liver. In fact, these two patients were diagnosed with HAdV hepatitis. Similar heterogeneous enhancement and clear low attenuation areas have been described in the previous reports and were radiologically mistaken for metastases, other infections, or hepatolenticular degeneration (HLD) (<xref ref-type="bibr" rid="B24">24</xref>&#x02013;<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B50">50</xref>). Therefore, these different imaging findings and interpretations confirm the significance of histological evaluation of liver biopsy. Simultaneously, it is significant to be familiar with the most related key radiological features and then combined with the key clinical information, which is probably afforded sufficient information to describe the characteristics of the lesion. In the end, we can also successfully differentiate HAdV hepatitis from other diseases.</p>
</sec>
<sec id="s7">
<title>Diagnosis of HAdV</title>
<p>Human adenovirus can be detected through indirect or direct immunofluorescence, routine or shell bottle culture, together with the PCR of the infected sites (e.g., urine, stool, blood, swabs, nasopharyngeal aspirates, bronchoalveolar lavage, and washings) (<xref ref-type="bibr" rid="B51">51</xref>). The available diagnostic approaches for the infections of adenovirus [e.g., electron microscopy, culture, histopathology, detection of antibodies, direct antigen detection, PCR, immunohistochemistry, and <italic>in situ</italic> hybridization (ISH)] are determined by the collected samples and infection location.</p>
<p>Traditional or shell bottle culture is a gold standard, but it may not be sensitive to some samples (e.g., blood) and is probably take several days to induce the cytopathic effect (CPE). Adenovirus-related CPE is typically expressed as the grapevine, with irregular aggregates composed of enlarged circular cells revealing characteristic refractable intranuclear inclusions. CPE slowly develops and variations can be found within 28 days after the inoculation, most of which occur in the first culture week (<xref ref-type="bibr" rid="B12">12</xref>). The time of detection is determined by various factors, containing the serotypes or adenovirus subsets, viral load inoculated, culture condition, or cell lines utilized.</p>
<p>The electron microscopy can be employed for identifying the HAdV, particularly in stool. What is more, immunoelectron microscopy can improve the detection sensitivity. Generally speaking, although the number of enteric adenoviruses in stool is much larger than the number of isolates of respiratory adenovirus, in the stool, the existence of adenovirus cannot diagnose GI diseases. In the past, these approaches for the identification of adenovirus in the clinical specimens (especially GI specimens) were a main method, but their convention use has decreased in the past several years.</p>
<p>Histopathological evaluation is still a gold standard for diagnosing the diseases of invasive adenovirus. This technique for the detection of adenovirus has been described above.</p>
<p>Fluorescent antibody (FA) detection can be employed for the direct detection (generally from the respiratory samples), simultaneously for identifying virus isolates cultured by shell bottle method and traditional methods. Despite FA is extensively utilized, its sensitivity is restricted, especially in detecting the double infection (<xref ref-type="bibr" rid="B52">52</xref>).</p>
<p>Adenovirus nucleic acid can be determined through a variety of molecular approaches. Since the N-terminal area of hexagonal gene and trans-activated area of E1A are very conservative between serotypes, primers for these areas are generally utilized for PCR detection (<xref ref-type="bibr" rid="B53">53</xref>).</p>
<p>Polymerase chain reaction is an extensively utilized approach to detect the adenovirus through amplifying and determining virus genome, which greatly replaces the virus culture together with other old diagnostic approaches (<xref ref-type="bibr" rid="B10">10</xref>). Through polymerase chain reaction, we can test stool, blood, respiratory secretions, and tissue specimens. Quantitative and qualitative PCR approaches can be utilized. Simultaneously, PCR possesses high rapidity and sensitivity. A novel molecular detection approach known as immune-PCR is expected to improve the sensitivity of fecal detection owing to it eliminates the requirement for extracting the nucleic acid (<xref ref-type="bibr" rid="B54">54</xref>).</p>
<p>Immunohistochemical staining can determine the HAdV hexagonal antigen existed in the tissue (<xref ref-type="bibr" rid="B55">55</xref>). In ISH together with IHC technologies for detecting the adenovirus is conducive to identify the infection of HAdV in tissue sections and enhance the sensitivity as an auxiliary means of morphological examination. In the meantime, they may localize disease and provide evidence for causality (<xref ref-type="bibr" rid="B56">56</xref>).</p>
<p>Although the sensitivity of instance electron microscopy is low, the specificity is high. The sensitivity of direct antigen detection is lower than the specificity. On the contrary, the sensitivity of detection of antibodies is higher than the specificity. Combining ISH with immunohistochemistry techniques for the detection of adenoviruses can increase the sensitivity. PCR&#x00027;s both sensitivity and specificity are high. The sensitivity and specificity of culture and histopathology are also high, but they are more time-consuming and laborious. In conclusion, despite HAdV-positive detection may be regarded as the diagnosis of the adenovirus infection in a proper clinical environment, PCR of infection site or pathological evidence of the invasive adenovirus disease is still required to determine causality.</p>
</sec>
<sec id="s8">
<title>Clinical Features of HAdV Infection</title>
<sec>
<title>Respiratory Tract Involvement</title>
<p>Human adenovirus makes up at least 5&#x02013;10% of childhood infections and 1&#x02013;7% of the adult respiratory infections (RTIs) (<xref ref-type="bibr" rid="B12">12</xref>). For the HAdV RTI, its characteristic symptoms consist of fever, cough, tonsillitis, and pharyngitis. Among children, GI symptoms may be present concomitantly (<xref ref-type="bibr" rid="B57">57</xref>). Symptoms are usually self-limiting (within 2 weeks) in immunocompetent patients, and infection can lead to the type-specific immunity. Nonetheless, pneumonia appears in 20% of infants and newborns, and death from HAdV pneumonia has been expresses in formerly healthy adults or children (<xref ref-type="bibr" rid="B58">58</xref>). In 10&#x02013;30% of cases, immunocompromised persons may develop into severe respiratory failure and/or transmission, and mortality rate of severe HAdV pneumonia may be as high as 50% (<xref ref-type="bibr" rid="B59">59</xref>).</p>
</sec>
<sec>
<title>Ocular Involvement</title>
<p>Manifestations of ocular HAdV infection consist of non-specific conjunctivitis, pharyngeal conjunctival fever, and EKC (<xref ref-type="bibr" rid="B60">60</xref>). The most prevalent species related to the ocular mucosa acute infection is HAdV-D, which causes the clinical ocular pathogenesis, whereas HAdV-D is reported to be related to EKC outbreak, which may induce vision loss, recurrent, or chronic keratitis. David Dyer, Xiaohong Zhou, Ashrafali Mohamed Ismail, James Chodosh, Jaya Rajaiya, and Donald Seto expressed the clinical pathology for this disease and the virus molecular phenotype inducing the epidemic EKC (<xref ref-type="bibr" rid="B8">8</xref>). What is more, conjunctivitis occurs predominantly with HAdV-B (<xref ref-type="bibr" rid="B61">61</xref>).</p>
</sec>
<sec>
<title>GI Infection</title>
<p>Acute HAdV infections of the GI tract occur predominantly with HAdV-F (notably HAdV-40 and&#x02212;41) and can cause a lot of symptoms, containing hemorrhagic colitis, diarrhea, gastroenteritis, pancreatitis, cholecystitis, and hepatitis (<xref ref-type="bibr" rid="B62">62</xref>). Even if the major position of the infection is respiratory tract, HAdV infections can also cause GI symptoms, particularly in young children (<xref ref-type="bibr" rid="B15">15</xref>). The researches have indicated that most invasive infections seem to be induced <italic>via</italic> the reactivation of virus. Adenovirus persists in children&#x00027;s GI tract. Intestinal epithelium is the major position of virus replication, which precedes the invasion event. As a result, regular monitoring of the existence and load of adenovirus in the fecal samples has become the main diagnostic approach of patient monitoring. However, the site of reactivation in the adult setting is unclear. Hence, peripheral blood sample monitoring is a conversion method for the adult patients.</p>
</sec>
<sec>
<title>Urinary Tract Infection</title>
<p>In patients undergoing HSCT and SOT, HAdV can induce urinary tract infections (UTIs). Its classical manifestations contain hematuria, dysuria, the dysfunction of renal transplantation and hemorrhagic cystitis (HC) (<xref ref-type="bibr" rid="B63">63</xref>). Despite there have been reports of dialysis-dependent or fatal renal failure, obstructive uropathy, necrotizing tubulointerstitial nephritis, and fatal dissemination, HAdV UTIs usually abate spontaneously. Most common species associated with HC is HAdV-B, including HAdV-11, -34, -35, -3, -7, and -21 (<xref ref-type="bibr" rid="B64">64</xref>). Diagnosis can be confirmed through culture or PCR in serology or urine, and the viral infection of the renal tubular epithelial cells containing intranuclear inclusions and stained cells was demonstrated by renal biopsy.</p>
</sec>
<sec>
<title>Liver Infection</title>
<p>We almost reviewed all case reports in the recent 10 years and summarized the liver function index of these patients (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B65">65</xref>&#x02013;<xref ref-type="bibr" rid="B75">75</xref>). The average of ALT was 1,607 U/L, with a range from 87 to 9,150 U/L. The average of AST was 4,671 U/L, with a range from 76 to 16,050 U/L. The average of TBIL was 6.2 mg/dL, with a range from 0.4 to 31.3 mg/dL. The average of ALP was 820 U/L, with a range from 123 to 2,802 U/L. The average of &#x003B3;-glutamyltransferase was 790 U/L, with a range from 98 to 1,563 U/L. In a case report written by Kawashima et al., their observation raises the possibility that elevated &#x003B3;-glutamyltransferase could be a sentinel marker for HAdV hepatitis. In subsequent studies by Onda et al., they also suggest that an increase in &#x003B3;GTP (100 IU/L or more) appears more than 2 weeks before the onset of hepatitis may be useful for the early diagnosis of HAdV hepatitis. All in all, adenovirus hepatitis is more common in children, the elderly, and adults with compromised immune systems than other types of hepatitis, and its onset is more acute. In other viral hepatitis, except viral hepatitis A and E often cause acute hepatitis, viral hepatitis B, C, and D usually cause chronic hepatitis. On the laboratory examination, adenovirus hepatitis shows markedly elevated liver enzymes, which should be differentiated from drug-induced liver injury. In addition, the other clinic features of HAdV hepatitis will be described below.</p>
</sec>
<sec>
<title>Other Disease</title>
<p>Despite 10&#x02013;30% of HSCT recipients develop the disseminated disease with the infection of HAdV, in the immunocompetent hosts, disseminated infection of HAdV is rare (<xref ref-type="bibr" rid="B76">76</xref>). At the same time, rare manifestations for the infection of HAdV contain cardiomyopathy and myocarditis, meningitis, encephalitis, pulmonary dysplasia, mononucleosis-like syndrome, sudden infant death, and intussusception in children (<xref ref-type="bibr" rid="B77">77</xref>).</p>
</sec>
</sec>
<sec id="s9">
<title>Therapy of HAdV Hepatitis</title>
<p>The first and most significant treatment is still the reduced immunosuppression and supportive care. Nevertheless, there do not exist consensus on which immunosuppressive drugs to stop or decrease and the time to restart immunosuppression. Remission of viremia after reduction of immunosuppression shows the significance of the immune recovery during infection (<xref ref-type="bibr" rid="B78">78</xref>, <xref ref-type="bibr" rid="B79">79</xref>). On the other hand, it is difficult to identify the primary cause that is on account of an increase in antiviral therapy and a decrease in immunosuppression or the combination of these treatments in the resolution of the disease (<xref ref-type="bibr" rid="B80">80</xref>).</p>
<p>Timely initiation of antiviral therapy is necessary to prevent or successfully control human adenovirus hepatitis. The currently available immunotherapy and agents against HAdV based on the nucleoside analogs are not supported through the randomized prospective clinical experiment of brincidofovir and cidofovir (cidofovir&#x00027;s lipid-conjugated prodrug) that seem to be useful for treating progressive, disseminated and severe human adenovirus diseases, which include HAdV hepatitis.</p>
<p>Despite cidofovir is a cytosine nucleotide analog, which suppresses the viral DNA polymerase, has been reported that its efficacy depends partly on patients&#x00027; partial immune recovery, the most commonly used antiviral medicant is still cidofovir. Meanwhile, cidofovir has main side effects, including severe nephrotoxicity and neutropenia. So, the side effects of cidofovir limit its wide application in clinic.</p>
<p>In comparison with cidofovir, brincidofovir has less renal toxicity and has better oral biological availability and enables administration once or two times a week. Although brincidofovir also has some toxic side effects, such as GI symptoms, it is the most effective anti-adenoviral medicant. The recent studies used the lipid conjugate of cidofovir to give a preemptive treatment in patients with HAdV and reveal promising outcomes, namely, the drug allows a considerable proportion of patients to clear HAdV, even without the reconstitution of immune (<xref ref-type="bibr" rid="B81">81</xref>, <xref ref-type="bibr" rid="B82">82</xref>). A few reports have emphasized the life-saving potentiality of this drug for the immunocompromised patients (<xref ref-type="bibr" rid="B83">83</xref>, <xref ref-type="bibr" rid="B84">84</xref>).</p>
<p>Ribavirin is a type of nucleoside analog that appears to possess an antiviral activity only against HAdV-c (serotypes 6, 5, 2, and 1) (<xref ref-type="bibr" rid="B85">85</xref>). However, the significant anti-adenovirus activity of ribavirin in patients is uncertain, and its main side effect is anemia. All in all, ribavirin is not recommended to treat serious HAdV infections. Ganciclovir is a common antiviral drug, but it needs the phosphorylation to reach the active condition. Nevertheless, human adenovirus is unreasonable to treat adenovirus infection owing to the lack of thymidine kinase (<xref ref-type="bibr" rid="B86">86</xref>). The efficacy of other commonly used drugs, which include foscarnet and vidarabine, in treating HAdV hepatitis is highly questionable.</p>
<p>Besides using antiviral medicant, intravenous immunoglobulin may be beneficial, especially in patients with hypogammaglobulinemia. In addition to the treatments described above, immunotherapy (for instance the adoptive transfer for the treatment of HAdV-specific T cells) has been employed for exceeding 10 years to combat invasive HAdV infections that do not respond to virostatic drugs (<xref ref-type="bibr" rid="B87">87</xref>). This is an adoptive immunotherapy that could result in a polyclonal T-cell graft, containing enriched numbers of HAdV-specific CD4&#x0002B; and CD8&#x0002B; T cells. Additionally, it would be better that making a transfer of specific T cells before the onset of symptoms and increasing viral load. The potential side effect of adoptive T-cell immunotherapy is GVHD. Because the isolation procedure is an enrichment of virus-specific T cells and it may result in a mixed population with a potential contamination of alloreactive T cells, which carry the risk of GVHD induction and aggravation of viral infections. Several studies have suggested that the existence of HAdV-specific T cells and immune reconstitution are very significant to clear the infection of HAdV, which gives a foundation for the treatment of human adenovirus infection (<xref ref-type="bibr" rid="B88">88</xref>&#x02013;<xref ref-type="bibr" rid="B90">90</xref>). The initial studies had shown that timely initiation for the treatment is especially significant for controlling the infection of HAdV successfully. Proper immune cells from various sources have been investigated (<xref ref-type="bibr" rid="B87">87</xref>). Except for a variety of methods of separating HAdV-specific T cells from their respective SCT donors, other sources of virus-specific T cells were employed, containing T-cell line libraries constructed from healthy donors revealing prevalent HLA polymorphisms or partial HLA-matched third-party donors (<xref ref-type="bibr" rid="B87">87</xref>, <xref ref-type="bibr" rid="B91">91</xref>&#x02013;<xref ref-type="bibr" rid="B95">95</xref>). The clear link between successful virus control and timely immunotherapy initiation supports the concept of affording an off-the-shelf supply of HAdV-specific T cells (<xref ref-type="bibr" rid="B96">96</xref>, <xref ref-type="bibr" rid="B97">97</xref>). Simultaneously, in the recipients of child SCT, the average time span between the first onset of adenoviremia and HAdV amplification exceeding critical threshold in continuous stool samples was as long as 11 days (<xref ref-type="bibr" rid="B98">98</xref>). During this time, separation and amplification of Don-induced HAdV-specific T cells can also be adoptive transferred after or before viremia (<xref ref-type="bibr" rid="B92">92</xref>). Specifically, in high-risk groups, it can be imagined to produce the virus-specific T cells prior to allogeneic SCT to guarantee access to the targeted immunotherapy timely. In conclusion, immunotherapy is an important part of combating HAdV infection in immunocompromised patients because of the current limitations of antiviral drugs.</p>
</sec>
<sec id="s10">
<title>Summary of HAdV Hepatitis Case Report</title>
<p>In 2014, Ronan et al. published a review on the adenoviral hepatitis clinical characteristics, containing the follow-up reports as of July 2021. A number of 107 adenoviral hepatitis cases have been reported in the literature (<xref ref-type="bibr" rid="B21">21</xref>&#x02013;<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B65">65</xref>&#x02013;<xref ref-type="bibr" rid="B74">74</xref>). Next, we will summarize these cases briefly.</p>
<p>Of the 107 confirmed HAdV hepatitis cases, the great majority of the patients were children under the age of 18, and the proportion was 61% (<xref ref-type="table" rid="T2">Table 2</xref>). In contrast, 42 were adults. There were slightly more male patients than female patients. In our study, the recipients of liver transplant and bone marrow transplant are 48 and 27 cases, respectively, 15 cases received chemotherapy recently, and five cases were patients with serious combined immunodeficiency. Compared with the Ronan&#x00027;s article, the number of patients receiving bone marrow transplant has increased, probably because of hematology science is now better developed. HAdV hepatitis caused by other diseases does not change significantly from the past, except for the addition of one patient who was underlying chronic lymphocytic leukemia (CLL). Diagnosis of HAdV hepatitis was made by patients&#x00027; liver biopsy or on autopsy. The method used to identify adenovirus has been described above. Among 107 patients, the most common method was immunohistochemistry in the liver tissue. In the meantime, viral culture was also commonly used. The application ratio of these two methods was 62 and 61%, respectively, while the application proportion of electron microscopy was 45%. Comparatively speaking, PCR and ISH were relatively less used. Liver necrosis is the most prevalent histopathological manifestation. The stain cells and viral inclusion bodies could also be found in liver histopathology. Additionally, the initial symptom was fever in 84 patients. Other prevalent symptoms when present contained discomfort or drowsiness, jaundice, and diarrhea. In some situations, alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) also rapidly increased. Abdominal CT scan revealed that 15 of the 19 patients had multiple low-density lesions, while a single hypodense lesion was found in 3 of these patients. However, few positive findings were in CT imaging, suggesting the concealed of HAdV hepatitis.</p>
<table-wrap position="float" id="T2">
<label>Table 2</label>
<caption><p>Characteristics of 107 patients with HAdV hepatitis.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th valign="top" align="left"><bold>Basic conditions</bold></th>
<th valign="top" align="center"><bold>Number of patients</bold></th>
<th valign="top" align="center"><bold>Proportion of patients</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left" colspan="3"><bold>Age</bold></td>
</tr>
<tr>
<td valign="top" align="left">Pediatric (0&#x02013;17)</td>
<td valign="top" align="center">65</td>
<td valign="top" align="center">61%</td>
</tr>
<tr>
<td valign="top" align="left">Adult (&#x02265;18)</td>
<td valign="top" align="center">42</td>
<td valign="top" align="center">39%</td>
</tr>
<tr>
<td valign="top" align="left" colspan="3"><bold>Gender</bold></td>
</tr>
<tr>
<td valign="top" align="left">Male</td>
<td valign="top" align="center">42</td>
<td valign="top" align="center">54%</td>
</tr>
<tr>
<td valign="top" align="left">Female</td>
<td valign="top" align="center">36</td>
<td valign="top" align="center">46%</td>
</tr>
<tr>
<td valign="top" align="left" colspan="3"><bold>Underlying condition</bold></td>
</tr>
<tr>
<td valign="top" align="left">Liver transplant</td>
<td valign="top" align="center">48</td>
<td valign="top" align="center">45%</td>
</tr>
<tr>
<td valign="top" align="left">Bone marrow transplant</td>
<td valign="top" align="center">27</td>
<td valign="top" align="center">25%</td>
</tr>
<tr>
<td valign="top" align="left">Chemotherapy</td>
<td valign="top" align="center">15</td>
<td valign="top" align="center">14%</td>
</tr>
<tr>
<td valign="top" align="left">SCID</td>
<td valign="top" align="center">5</td>
<td valign="top" align="center">4%</td>
</tr>
<tr>
<td valign="top" align="left">HIV infection</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">4%</td>
</tr>
<tr>
<td valign="top" align="left">Renal transplant</td>
<td valign="top" align="center">2</td>
<td valign="top" align="center">2%</td>
</tr>
<tr>
<td valign="top" align="left">Heart transplant</td>
<td valign="top" align="center">2</td>
<td valign="top" align="center">2%</td>
</tr>
<tr>
<td valign="top" align="left">Neonates (no known comorbidity)</td>
<td valign="top" align="center">2</td>
<td valign="top" align="center">2%</td>
</tr>
<tr>
<td valign="top" align="left">CLL</td>
<td valign="top" align="center">2</td>
<td valign="top" align="center">2%</td>
</tr>
<tr>
<td valign="top" align="left" colspan="3"><bold>Method of adenovirus detection in the liver (</bold><italic><bold>N</bold></italic> <bold>&#x0003D;</bold> <bold>107)</bold></td>
</tr>
<tr>
<td valign="top" align="left">Immunohistochemistry</td>
<td valign="top" align="center">66</td>
<td valign="top" align="center">62%</td>
</tr>
<tr>
<td valign="top" align="left">Culture</td>
<td valign="top" align="center">65</td>
<td valign="top" align="center">61%</td>
</tr>
<tr>
<td valign="top" align="left">Electron microscopy</td>
<td valign="top" align="center">48</td>
<td valign="top" align="center">45%</td>
</tr>
<tr>
<td valign="top" align="left">Polymerase chain reaction</td>
<td valign="top" align="center">16</td>
<td valign="top" align="center">15%</td>
</tr>
<tr>
<td valign="top" align="left"><italic>In situ</italic> hybridization</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">4%</td>
</tr>
<tr>
<td valign="top" align="left" colspan="3"><bold>Liver histopathology (</bold><italic><bold>N</bold></italic> <bold>&#x0003D;</bold> <bold>82)</bold></td>
</tr>
<tr>
<td valign="top" align="left">Necrosis</td>
<td valign="top" align="center">72</td>
<td valign="top" align="center">88%</td>
</tr>
<tr>
<td valign="top" align="left">Intranuclear inclusions</td>
<td valign="top" align="center">55</td>
<td valign="top" align="center">67%</td>
</tr>
<tr>
<td valign="top" align="left">Smudge cells</td>
<td valign="top" align="center">21</td>
<td valign="top" align="center">26%</td>
</tr>
<tr>
<td valign="top" align="left" colspan="3"><bold>Presenting symptoms (</bold><italic><bold>N</bold></italic> <bold>&#x0003D;</bold> <bold>92)</bold></td>
</tr>
<tr>
<td valign="top" align="left">Fever</td>
<td valign="top" align="center">84</td>
<td valign="top" align="center">91%</td>
</tr>
<tr>
<td valign="top" align="left">Lethargy/malaise</td>
<td valign="top" align="center">22</td>
<td valign="top" align="center">24%</td>
</tr>
<tr>
<td valign="top" align="left">Diarrhea</td>
<td valign="top" align="center">13</td>
<td valign="top" align="center">14%</td>
</tr>
<tr>
<td valign="top" align="left">Jaundice</td>
<td valign="top" align="center">8</td>
<td valign="top" align="center">9%</td>
</tr>
<tr>
<td valign="top" align="left" colspan="3"><bold>CT imaging findings (</bold><italic><bold>N</bold></italic> <bold>&#x0003D;</bold> <bold>19)</bold></td>
</tr>
<tr>
<td valign="top" align="left">Multiple hypodense lesions</td>
<td valign="top" align="center">15</td>
<td valign="top" align="center">79%</td>
</tr>
<tr>
<td valign="top" align="left">Single hypodense lesion</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">16%</td>
</tr>
<tr>
<td valign="top" align="left">Normal</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">5%</td>
</tr>
<tr>
<td valign="top" align="left" colspan="3"><bold>Outcome (</bold><italic><bold>N</bold></italic> <bold>&#x0003D;</bold> <bold>107)</bold></td>
</tr>
<tr>
<td valign="top" align="left">Survival</td>
<td valign="top" align="center">30</td>
<td valign="top" align="center">28%</td>
</tr>
<tr>
<td valign="top" align="left">Death</td>
<td valign="top" align="center">77</td>
<td valign="top" align="center">72%</td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left"><bold>Treatment (</bold><italic><bold>N</bold></italic> <bold>&#x0003D;</bold> <bold>59)</bold></td>
<td valign="top" align="center"><bold>Number of patients</bold></td>
<td valign="top" align="center"><bold>Survival</bold></td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left">Reduced immunosuppression</td>
<td valign="top" align="center">27</td>
<td valign="top" align="center">15</td>
</tr>
<tr>
<td valign="top" align="left">Reduced immunosuppression &#x0002B; antiviral</td>
<td valign="top" align="center">9 cidofovir</td>
<td valign="top" align="center">7</td>
</tr>
<tr>
<td/>
<td valign="top" align="center">2 ribavirin</td>
<td valign="top" align="center">1</td>
</tr>
<tr>
<td valign="top" align="left">Liver re-transplantation</td>
<td valign="top" align="center">12</td>
<td valign="top" align="center">6</td>
</tr>
<tr>
<td valign="top" align="left">Cidofovir &#x0002B; IVIG</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">2</td>
</tr>
<tr>
<td valign="top" align="left">IVIG alone</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">0</td>
</tr>
<tr>
<td valign="top" align="left">Cidofovir alone</td>
<td valign="top" align="center">2</td>
<td valign="top" align="center">0</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>In 107 cases, only 59 patients&#x00027; treatments were accurately described, while the most useful treatment was reduced immunosuppression (<xref ref-type="table" rid="T2">Table 2</xref>). Of the 27 patients, the only improvement of treatment was the decrease of immunosuppression, of which 15 survived. A number of eight other patients with antiviral drugs (ribavirin or cidofovir) and immunosuppressants also survived. Among the 12 patients, 6 were successful in liver transplantation. Intravenous immunoglobulin therapy alone or cidofovir therapy alone was unsuccessful in all 6 patients of HAdV hepatitis, while 2 of 3 patients survived using IVIG and cidofovir together. It was unfortunate that the overall prognosis for patients with hepatitis HAdV is poor, with only 30 of 107 published cases (28%) surviving. In conclusion, the great majority of HAdV hepatitis cases are fatal. The hepatitis of HAdV has few characteristic signs and symptoms, but it is generally hard to diagnose and delayed treatment is not uncommon.</p>
</sec>
<sec sec-type="conclusions" id="s11">
<title>Conclusions</title>
<p>Among viral infections, human adenovirus infection is relatively rare, but HAdV infection is also of great clinical significance. Among immunocompetent patients, HAdV infection usually causes upper respiratory, GI, or conjunctival involvement, and the most cases are self-limited. In contrast, disseminated and severe infections (e.g., pneumonitis, gastroenteritis, hemorrhagic cystitis, nephritis, encephalitis, and enterocolitis) are more common among immunocompetent patients. However, HAdV hepatitis is uncommon, the common causes of hepatitis contain drugs, venous obstruction, ischemia, autoimmune hepatitis, toxins, and metabolic cause together with infectious causes, involving CMV, VZV, hepatitis A-E, EBV, and HSV. In our review, we mainly introduced human adenovirus hepatitis. And we summarize some characteristics of HAdV hepatitis (<xref ref-type="table" rid="T3">Table 3</xref>). The high-risk factors of HAdV hepatitis include SOT, the virus infection of human immunodeficiency, chemotherapy, the transplantation of hematopoietic stem cell, SCID, and lymphoma. The review of reported cases with HAdV hepatitis shows that the most common risk factor is liver transplantation. With the development of hematology science, the number of patients receiving bone marrow transplant has increased, and the proportion of this factor is also increasing. There are few studies on the pathogenesis of human adenovirus hepatitis, but they mainly focus on the study of adenovirus vector-induced liver disease. According to the current reports, we found that NK cells and CD8&#x0002B; T cells play a major effect in the elimination of hepatocytes that infected with vector based on HAdV-C5. We expect that there are more innate and adaptive immunity studies related to HAdV hepatitis in the future. Now, the available diagnostic methods of HAdV include culture, electron microscopy, histopathology, detection of antibodies, direct antigen detection, PCR, immunohistochemistry, and ISH. Surprisingly, there is an even newer detection method, next-generation sequencing, which can help to type adenoviruses. In an appropriate clinical setting, a positive next-generation sequencing (NGS) test can be considered a diagnosis of adenovirus infection. So far, few cases that used NGS to detect HAdV have been reported, and the effectiveness of this method remains to be observed. Histopathologic assessment is a gold standard for diagnosing the HAdV hepatitis, and the histopathologic features include hepatic necrosis, viral inclusions, and smudge cells. For the HAdV hepatitis, its imaging characteristics are generally non-specific, but radiology exerts a more significant effect in suspected patients with HAdV hepatitis and is conducive to eliminate other causes. In our review, we can find multiple hypodense lesions or single hypodense lesion in CT among some patients with HAdV hepatitis. However, the positive findings are still relatively rare and are still not supported by large sample data. In terms of treatment, despite the presently available anti-HAdV drugs based on the nucleoside analogs are not supported through the prospective randomized clinical trials, antiviral medicant is partly useful. Besides, intravenous immunoglobulin and immunotherapy (e.g., adoptive transfer of HAdV-specific T-cell therapy) may be beneficial. More importantly, reducing immunosuppression is necessary. In the end, 107 human adenovirus hepatitis cases reported in the literature were gathered. We find that the clinical symptoms of HAdV hepatitis are not typical, and the most common symptom is fever. Other symptoms include lethargy or malaise, diarrhea, and jaundice. In some situations, alkaline phosphatase, ALT, and AST also rapidly increased. Generally speaking, HAdV hepatitis possesses few characteristic signs and symptoms, but it is often hard to diagnose and delayed treatment is not uncommon. So, HAdV hepatitis is usually fatal. We expect to collect further information on large samples to find clinical features of human adenovirus hepatitis in the next study.</p>
<table-wrap position="float" id="T3">
<label>Table 3</label>
<caption><p>Characteristics of HAdV hepatitis.</p></caption>
<table frame="hsides" rules="groups">
<tbody><tr>
<td valign="top" align="left">The route of infection</td>
<td valign="top" align="left">Inhalation of infected aerosols <break/> Person-to-person contact <break/> Fecal-oral route <break/> Direct conjunctival inoculation <break/> Contact with infected blood or tissue</td>
</tr>
<tr>
<td valign="top" align="left">Methods of detection</td>
<td valign="top" align="left">Instance electron microscopy <break/> Culture <break/> Histopathology <break/> Detection of antibodies <break/> Direct antigen detection <break/> Polymerase chain reaction <break/> Immunohistochemistry <break/> <italic>In situ</italic> hybridization</td>
</tr>
<tr>
<td valign="top" align="left">Treatment</td>
<td valign="top" align="left">Reduced immunosuppression <break/> Reduced immunosuppression &#x0002B; antiviral drug (cidofovir/ ribavirin) <break/> Liver re-transplantation <break/> Cidofovir &#x0002B; IVIG <break/> IVIG alone <break/> Cidofovir alone <break/> Brincidofovir <break/> Adoptive transfer of HAdV-specific T cell therapy</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s12">
<title>Author Contributions</title>
<p>NZ and XH designed the concept of the study. NZ, XH, and YW wrote the first draft of the manuscript. HR and KW edited the subsequent versions of the manuscript. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec sec-type="funding-information" id="s13">
<title>Funding</title>
<p>The Chinese Foundation for Hepatitis Prevention and Control (31010303010946, TGQB20180371) sponsored this study.</p>
</sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s14">
<title>Publisher&#x00027;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rowe</surname> <given-names>WP</given-names></name> <name><surname>Huebner</surname> <given-names>RJ</given-names></name> <name><surname>Gilmore</surname> <given-names>LK</given-names></name> <name><surname>Parrott</surname> <given-names>RH</given-names></name> <name><surname>Ward</surname> <given-names>TG</given-names></name></person-group>. <article-title>Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture</article-title>. <source>Proc Soc Exp Biol Med.</source> (<year>1953</year>) <volume>84</volume>:<fpage>570</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.3181/00379727-84-20714</pub-id><pub-id pub-id-type="pmid">13134217</pub-id></citation></ref>
<ref id="B2">
<label>2.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hilleman</surname> <given-names>MR</given-names></name> <name><surname>Werner</surname> <given-names>JH</given-names></name></person-group>. <article-title>Recovery of new agent from patients with acute respiratory illness</article-title>. <source>Proc Soc Exp Biol Med.</source> (<year>1954</year>) <volume>85</volume>:<fpage>183</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.3181/00379727-85-20825</pub-id><pub-id pub-id-type="pmid">13134329</pub-id></citation></ref>
<ref id="B3">
<label>3.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greber</surname> <given-names>UF</given-names></name> <name><surname>Flatt</surname> <given-names>JW</given-names></name></person-group>. <article-title>Adenovirus entry: from infection to immunity</article-title>. <source>Ann Rev Virol.</source> (<year>2019</year>) <volume>6</volume>:<fpage>177</fpage>&#x02013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-virology-092818-015550</pub-id><pub-id pub-id-type="pmid">31283442</pub-id></citation></ref>
<ref id="B4">
<label>4.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nemerow</surname> <given-names>GR</given-names></name> <name><surname>Pache</surname> <given-names>L</given-names></name> <name><surname>Reddy</surname> <given-names>V</given-names></name> <name><surname>Stewart</surname> <given-names>PL</given-names></name></person-group>. <article-title>Insights into adenovirus host cell interactions from structural studies</article-title>. <source>Virology.</source> (<year>2009</year>) <volume>384</volume>:<fpage>380</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2008.10.016</pub-id><pub-id pub-id-type="pmid">19019405</pub-id></citation></ref>
<ref id="B5">
<label>5.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benevento</surname> <given-names>M</given-names></name> <name><surname>Di Palma</surname> <given-names>S</given-names></name> <name><surname>Snijder</surname> <given-names>J</given-names></name> <name><surname>Moyer</surname> <given-names>CL</given-names></name> <name><surname>Reddy</surname> <given-names>VS</given-names></name> <name><surname>Nemerow</surname> <given-names>GR</given-names></name> <etal/></person-group>. <article-title>Adenovirus composition, proteolysis, and disassembly studied by in-depth qualitative and quantitative proteomics</article-title>. <source>J Biol Chem.</source> (<year>2014</year>) <volume>289</volume>:<fpage>11421</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M113.537498</pub-id><pub-id pub-id-type="pmid">24591515</pub-id></citation></ref>
<ref id="B6">
<label>6.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname> <given-names>VS</given-names></name> <name><surname>Natchiar</surname> <given-names>SK</given-names></name> <name><surname>Stewart</surname> <given-names>PL</given-names></name> <name><surname>Nemerow</surname> <given-names>GR</given-names></name></person-group>. <article-title>Crystal structure of human adenovirus at 3.5 A resolution</article-title>. <source>Science.</source> (<year>2010</year>) <volume>329</volume>:<fpage>1071</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1126/science.1187292</pub-id><pub-id pub-id-type="pmid">20798318</pub-id></citation></ref>
<ref id="B7">
<label>7.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uhnoo</surname> <given-names>I</given-names></name> <name><surname>Wadell</surname> <given-names>G</given-names></name> <name><surname>Svensson</surname> <given-names>L</given-names></name> <name><surname>Johansson</surname> <given-names>ME</given-names></name></person-group>. <article-title>Importance of enteric adenoviruses 40 and 41 in acute gastroenteritis in infants and young children</article-title>. <source>J Clin Microbiol.</source> (<year>1984</year>) <volume>20</volume>:<fpage>365</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1128/jcm.20.3.365-372.1984</pub-id><pub-id pub-id-type="pmid">6092424</pub-id></citation></ref>
<ref id="B8">
<label>8.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ismail</surname> <given-names>AM</given-names></name> <name><surname>Zhou</surname> <given-names>X</given-names></name> <name><surname>Dyer</surname> <given-names>DW</given-names></name> <name><surname>Seto</surname> <given-names>D</given-names></name> <name><surname>Rajaiya</surname> <given-names>J</given-names></name> <name><surname>Chodosh</surname> <given-names>J</given-names></name></person-group>. <article-title>Genomic foundations of evolution and ocular pathogenesis in human adenovirus species D</article-title>. <source>FEBS Lett.</source> (<year>2019</year>) <volume>593</volume>:<fpage>3583</fpage>&#x02013;<lpage>608</lpage>. <pub-id pub-id-type="doi">10.1002/1873-3468.13693</pub-id><pub-id pub-id-type="pmid">31769017</pub-id></citation></ref>
<ref id="B9">
<label>9.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname> <given-names>JP</given-names> <suffix>3rd</suffix></name> <name><surname>Kajon</surname> <given-names>AE</given-names></name></person-group>. <article-title>Adenovirus: epidemiology, global spread of novel serotypes, and advances in treatment and prevention</article-title>. <source>Semin Respir Crit Care Med.</source> (<year>2016</year>) <volume>37</volume>:<fpage>586</fpage>&#x02013;<lpage>602</lpage>. <pub-id pub-id-type="doi">10.1055/s-0036-1584923</pub-id><pub-id pub-id-type="pmid">27486739</pub-id></citation></ref>
<ref id="B10">
<label>10.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lion</surname> <given-names>T</given-names></name></person-group>. <article-title>Adenovirus infections in immunocompetent and immunocompromised patients</article-title>. <source>Clin Microbiol Rev.</source> (<year>2014</year>) <volume>27</volume>:<fpage>441</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.00116-13</pub-id><pub-id pub-id-type="pmid">31896387</pub-id></citation></ref>
<ref id="B11">
<label>11.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chandra</surname> <given-names>N</given-names></name> <name><surname>Fr&#x000E4;ngsmyr</surname> <given-names>L</given-names></name> <name><surname>Imhof</surname> <given-names>S</given-names></name> <name><surname>Caraballo</surname> <given-names>R</given-names></name> <name><surname>Elofsson</surname> <given-names>M</given-names></name> <name><surname>Arnberg</surname> <given-names>N</given-names></name></person-group>. <article-title>Sialic acid-containing glycans as cellular receptors for ocular human adenoviruses: implications for tropism and treatment</article-title>. <source>Viruses.</source> (<year>2019</year>) 11. <pub-id pub-id-type="doi">10.3390/v11050395</pub-id><pub-id pub-id-type="pmid">31035532</pub-id></citation></ref>
<ref id="B12">
<label>12.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ison</surname> <given-names>MG</given-names></name></person-group>. <article-title>Adenovirus infections in transplant recipients</article-title>. <source>Clin Infect Dis.</source> (<year>2006</year>) <volume>43</volume>:<fpage>331</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1086/505498</pub-id><pub-id pub-id-type="pmid">16804849</pub-id></citation></ref>
<ref id="B13">
<label>13.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname> <given-names>LS</given-names></name> <name><surname>Taylor</surname> <given-names>B</given-names></name> <name><surname>Reimels</surname> <given-names>W</given-names></name> <name><surname>Barrett</surname> <given-names>FF</given-names></name> <name><surname>Devincenzo</surname> <given-names>JP</given-names></name></person-group>. <article-title>Adenovirus 7a: a community-acquired outbreak in a children&#x00027;s hospital</article-title>. <source>Pediatr Infect Dis J.</source> (<year>2000</year>) <volume>19</volume>:<fpage>996</fpage>&#x02013;<lpage>1000</lpage>. <pub-id pub-id-type="doi">10.1097/00006454-200010000-00011</pub-id><pub-id pub-id-type="pmid">11055603</pub-id></citation></ref>
<ref id="B14">
<label>14.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mattner</surname> <given-names>F</given-names></name> <name><surname>Sykora</surname> <given-names>KW</given-names></name> <name><surname>Meissner</surname> <given-names>B</given-names></name> <name><surname>Heim</surname> <given-names>A</given-names></name></person-group>. <article-title>An adenovirus type F41 outbreak in a pediatric bone marrow transplant unit: analysis of clinical impact and preventive strategies</article-title>. <source>Pediatr Infect Dis J.</source> (<year>2008</year>) <volume>27</volume>:<fpage>419</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1097/INF.0b013e3181658c46</pub-id><pub-id pub-id-type="pmid">18382384</pub-id></citation></ref>
<ref id="B15">
<label>15.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname> <given-names>SY</given-names></name> <name><surname>Lee</surname> <given-names>CN</given-names></name> <name><surname>Lin</surname> <given-names>PH</given-names></name> <name><surname>Huang</surname> <given-names>HH</given-names></name> <name><surname>Chang</surname> <given-names>LY</given-names></name> <name><surname>Ko</surname> <given-names>W</given-names></name> <etal/></person-group>. <article-title>A community-derived outbreak of adenovirus type 3 in children in Taiwan between 2004 and 2005</article-title>. <source>J Med Virol.</source> (<year>2008</year>) <volume>80</volume>:<fpage>102</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.21045</pub-id><pub-id pub-id-type="pmid">18041026</pub-id></citation></ref>
<ref id="B16">
<label>16.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kajon</surname> <given-names>AE</given-names></name> <name><surname>Dickson</surname> <given-names>LM</given-names></name> <name><surname>Metzgar</surname> <given-names>D</given-names></name> <name><surname>Houng</surname> <given-names>HS</given-names></name> <name><surname>Lee</surname> <given-names>V</given-names></name> <name><surname>Tan</surname> <given-names>BH</given-names></name></person-group>. <article-title>Outbreak of febrile respiratory illness associated with adenovirus 11a infection in a Singapore military training cAMP</article-title>. <source>J Clin Microbiol.</source> (<year>2010</year>) <volume>48</volume>:<fpage>1438</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.01928-09</pub-id><pub-id pub-id-type="pmid">20129957</pub-id></citation></ref>
<ref id="B17">
<label>17.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abinun</surname> <given-names>M</given-names></name> <name><surname>Flood</surname> <given-names>TJ</given-names></name> <name><surname>Cant</surname> <given-names>AJ</given-names></name> <name><surname>Veys</surname> <given-names>P</given-names></name> <name><surname>Gennery</surname> <given-names>AR</given-names></name> <name><surname>Foster</surname> <given-names>HE</given-names></name> <etal/></person-group>. <article-title>Autologous T cell depleted haematopoietic stem cell transplantation in children with severe juvenile idiopathic arthritis in the UK (2000-2007)</article-title>. <source>Mol Immunol.</source> (<year>2009</year>) <volume>47</volume>:<fpage>46</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2008.12.029</pub-id><pub-id pub-id-type="pmid">19203795</pub-id></citation></ref>
<ref id="B18">
<label>18.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sandkovsky</surname> <given-names>U</given-names></name> <name><surname>Vargas</surname> <given-names>L</given-names></name> <name><surname>Florescu</surname> <given-names>DF</given-names></name></person-group>. <article-title>Adenovirus: current epidemiology and emerging approaches to prevention and treatment</article-title>. <source>Curr Infect Dis Rep.</source> (<year>2014</year>) <volume>16</volume>:<fpage>416</fpage>. <pub-id pub-id-type="doi">10.1007/s11908-014-0416-y</pub-id><pub-id pub-id-type="pmid">24908344</pub-id></citation></ref>
<ref id="B19">
<label>19.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Echavarr&#x000ED;a</surname> <given-names>M</given-names></name></person-group>. <article-title>Adenoviruses in immunocompromised hosts</article-title>. <source>Clin Microbiol Rev.</source> (<year>2008</year>) <volume>21</volume>:<fpage>704</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.00052-07</pub-id><pub-id pub-id-type="pmid">18854488</pub-id></citation></ref>
<ref id="B20">
<label>20.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kojaoghlanian</surname> <given-names>T</given-names></name> <name><surname>Flomenberg</surname> <given-names>P</given-names></name> <name><surname>Horwitz</surname> <given-names>MS</given-names></name></person-group>. <article-title>The impact of adenovirus infection on the immunocompromised host</article-title>. <source>Rev Med Virol.</source> (<year>2003</year>) <volume>13</volume>:<fpage>155</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1002/rmv.386</pub-id><pub-id pub-id-type="pmid">12740831</pub-id></citation></ref>
<ref id="B21">
<label>21.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ronan</surname> <given-names>BA</given-names></name> <name><surname>Agrwal</surname> <given-names>N</given-names></name> <name><surname>Carey</surname> <given-names>EJ</given-names></name> <name><surname>De Petris</surname> <given-names>G</given-names></name> <name><surname>Kusne</surname> <given-names>S</given-names></name> <name><surname>Seville</surname> <given-names>MT</given-names></name> <etal/></person-group>. <article-title>Fulminant hepatitis due to human adenovirus</article-title>. <source>Infection.</source> (<year>2014</year>) <volume>42</volume>:<fpage>105</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1007/s15010-013-0527-7</pub-id><pub-id pub-id-type="pmid">23979854</pub-id></citation></ref>
<ref id="B22">
<label>22.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schaberg</surname> <given-names>KB</given-names></name> <name><surname>Kambham</surname> <given-names>N</given-names></name> <name><surname>Sibley</surname> <given-names>RK</given-names></name> <name><surname>Higgins</surname> <given-names>JPT</given-names></name></person-group>. <article-title>Adenovirus hepatitis: clinicopathologic analysis of 12 consecutive cases from a single institution</article-title>. <source>Am J Surg Pathol.</source> (<year>2017</year>) <volume>41</volume>:<fpage>810</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/PAS.0000000000000834</pub-id><pub-id pub-id-type="pmid">28296681</pub-id></citation></ref>
<ref id="B23">
<label>23.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawashima</surname> <given-names>N</given-names></name> <name><surname>Muramatsu</surname> <given-names>H</given-names></name> <name><surname>Okuno</surname> <given-names>Y</given-names></name> <name><surname>Torii</surname> <given-names>Y</given-names></name> <name><surname>Kawada</surname> <given-names>J</given-names></name> <name><surname>Narita</surname> <given-names>A</given-names></name> <etal/></person-group>. <article-title>Fulminant adenovirus hepatitis after hematopoietic stem cell transplant: Retrospective real-time PCR analysis for adenovirus DNA in two cases</article-title>. <source>J Infect Chemother.</source> (<year>2015</year>) <volume>21</volume>:<fpage>857</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.jiac.2015.08.018</pub-id><pub-id pub-id-type="pmid">26423689</pub-id></citation></ref>
<ref id="B24">
<label>24.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Detrait</surname> <given-names>M</given-names></name> <name><surname>De Prophetis</surname> <given-names>S</given-names></name> <name><surname>Delville</surname> <given-names>JP</given-names></name> <name><surname>Komuta</surname> <given-names>M</given-names></name></person-group>. <article-title>Fulminant isolated adenovirus hepatitis 5 months after haplo-identical HSCT for AML</article-title>. <source>Clin Case Rep.</source> (<year>2015</year>) <volume>3</volume>:<fpage>802</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1002/ccr3.347</pub-id><pub-id pub-id-type="pmid">26509010</pub-id></citation></ref>
<ref id="B25">
<label>25.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname> <given-names>AA</given-names></name> <name><surname>Lo</surname> <given-names>EC</given-names></name> <name><surname>Rao</surname> <given-names>MS</given-names></name> <name><surname>Yang</surname> <given-names>GY</given-names></name></person-group>. <article-title>Concurrent acute necrotizing adenovirus hepatitis and enterocolitis in an adult patient after double cord blood stem cell transplant for refractory Crohn&#x00027;s disease</article-title>. <source>Int J Surg Pathol.</source> (<year>2015</year>) <volume>23</volume>:<fpage>404</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1177/1066896915587758</pub-id><pub-id pub-id-type="pmid">25998316</pub-id></citation></ref>
<ref id="B26">
<label>26.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Putra</surname> <given-names>J</given-names></name> <name><surname>Suriawinata</surname> <given-names>AA</given-names></name></person-group>. <article-title>Adenovirus hepatitis presenting as tumoral lesions in an immunocompromised patient</article-title>. <source>Ann Hepatol.</source> (<year>2014</year>) <volume>13</volume>:<fpage>827</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/S1665-2681(19)30986-X</pub-id><pub-id pub-id-type="pmid">25332270</pub-id></citation></ref>
<ref id="B27">
<label>27.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacque</surname> <given-names>N</given-names></name> <name><surname>Leblond</surname> <given-names>V</given-names></name></person-group>. <article-title>Chronic lymphocytic leukemia</article-title>. <source>Presse Med.</source> (<year>2019</year>) <volume>48</volume>:<fpage>807</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.lpm.2019.07.019</pub-id><pub-id pub-id-type="pmid">31447332</pub-id></citation></ref>
<ref id="B28">
<label>28.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname> <given-names>JP</given-names> <suffix>3rd</suffix></name> <name><surname>Fishbein</surname> <given-names>M</given-names></name> <name><surname>Echavarria</surname> <given-names>M</given-names></name></person-group>. <article-title>Adenovirus</article-title>. <source>Semin Respir Crit Care Med.</source> (<year>2011</year>) <volume>32</volume>:<fpage>494</fpage>&#x02013;<lpage>511</lpage>. <pub-id pub-id-type="doi">10.1055/s-0031-1283287</pub-id><pub-id pub-id-type="pmid">21858752</pub-id></citation></ref>
<ref id="B29">
<label>29.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alemany</surname> <given-names>R</given-names></name> <name><surname>Suzuki</surname> <given-names>K</given-names></name> <name><surname>Curiel</surname> <given-names>DT</given-names></name></person-group>. <article-title>Blood clearance rates of adenovirus type 5 in mice</article-title>. <source>J Gen Virol.</source> (<year>2000</year>) <volume>81</volume>:<fpage>2605</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1099/0022-1317-81-11-2605</pub-id><pub-id pub-id-type="pmid">11038370</pub-id></citation></ref>
<ref id="B30">
<label>30.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bradshaw</surname> <given-names>AC</given-names></name> <name><surname>Coughlan</surname> <given-names>L</given-names></name> <name><surname>Miller</surname> <given-names>AM</given-names></name> <name><surname>Alba</surname> <given-names>R</given-names></name> <name><surname>van Rooijen</surname> <given-names>N</given-names></name> <name><surname>Nicklin</surname> <given-names>SA</given-names></name> <etal/></person-group>. <article-title>Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses</article-title>. <source>J Control Rel.</source> (<year>2012</year>) <volume>164</volume>:<fpage>394</fpage>&#x02013;<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2012.05.025</pub-id><pub-id pub-id-type="pmid">22626939</pub-id></citation></ref>
<ref id="B31">
<label>31.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>JS</given-names></name> <name><surname>Xu</surname> <given-names>Z</given-names></name> <name><surname>Byrnes</surname> <given-names>AP</given-names></name></person-group>. <article-title>A quantitative assay for measuring clearance of adenovirus vectors by Kupffer cells</article-title>. <source>J Virol Methods.</source> (<year>2008</year>) <volume>147</volume>:<fpage>54</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.jviromet.2007.08.009</pub-id><pub-id pub-id-type="pmid">17850893</pub-id></citation></ref>
<ref id="B32">
<label>32.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>JS</given-names></name> <name><surname>Xu</surname> <given-names>Z</given-names></name> <name><surname>Tian</surname> <given-names>J</given-names></name> <name><surname>Stevenson</surname> <given-names>SC</given-names></name> <name><surname>Byrnes</surname> <given-names>AP</given-names></name></person-group>. <article-title>Interaction of systemically delivered adenovirus vectors with Kupffer cells in mouse liver</article-title>. <source>Hum Gene Ther.</source> (<year>2008</year>) <volume>19</volume>:<fpage>547</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1089/hum.2008.004</pub-id><pub-id pub-id-type="pmid">18447633</pub-id></citation></ref>
<ref id="B33">
<label>33.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Paolo</surname> <given-names>NC</given-names></name> <name><surname>Miao</surname> <given-names>EA</given-names></name> <name><surname>Iwakura</surname> <given-names>Y</given-names></name> <name><surname>Murali-Krishna</surname> <given-names>K</given-names></name> <name><surname>Aderem</surname> <given-names>A</given-names></name> <name><surname>Flavell</surname> <given-names>RA</given-names></name> <etal/></person-group>. <article-title>Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo</article-title>. <source>Immunity.</source> (<year>2009</year>) <volume>31</volume>:<fpage>110</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2009.04.015</pub-id><pub-id pub-id-type="pmid">19576795</pub-id></citation></ref>
<ref id="B34">
<label>34.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kalyuzhniy</surname> <given-names>O</given-names></name> <name><surname>Di Paolo</surname> <given-names>NC</given-names></name> <name><surname>Silvestry</surname> <given-names>M</given-names></name> <name><surname>Hofherr</surname> <given-names>SE</given-names></name> <name><surname>Barry</surname> <given-names>MA</given-names></name> <name><surname>Stewart</surname> <given-names>PL</given-names></name> <etal/></person-group>. <article-title>Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo</article-title>. <source>Proc Natl Acad Sci USA.</source> (<year>2008</year>) <volume>105</volume>:<fpage>5483</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0711757105</pub-id><pub-id pub-id-type="pmid">18391209</pub-id></citation></ref>
<ref id="B35">
<label>35.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waddington</surname> <given-names>SN</given-names></name> <name><surname>McVey</surname> <given-names>JH</given-names></name> <name><surname>Bhella</surname> <given-names>D</given-names></name> <name><surname>Parker</surname> <given-names>AL</given-names></name> <name><surname>Barker</surname> <given-names>K</given-names></name> <name><surname>Atoda</surname> <given-names>H</given-names></name> <etal/></person-group>. <article-title>Adenovirus serotype 5 hexon mediates liver gene transfer</article-title>. <source>Cell.</source> (<year>2008</year>) <volume>132</volume>:<fpage>397</fpage>&#x02013;<lpage>409</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2008.01.016</pub-id><pub-id pub-id-type="pmid">18267072</pub-id></citation></ref>
<ref id="B36">
<label>36.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shayakhmetov</surname> <given-names>DM</given-names></name> <name><surname>Gaggar</surname> <given-names>A</given-names></name> <name><surname>Ni</surname> <given-names>S</given-names></name> <name><surname>Li</surname> <given-names>ZY</given-names></name> <name><surname>Lieber</surname> <given-names>A</given-names></name></person-group>. <article-title>Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity</article-title>. <source>J Virol.</source> (<year>2005</year>) <volume>79</volume>:<fpage>7478</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.79.12.7478-7491.2005</pub-id><pub-id pub-id-type="pmid">15919903</pub-id></citation></ref>
<ref id="B37">
<label>37.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>Z</given-names></name> <name><surname>Zang</surname> <given-names>N</given-names></name> <name><surname>Fu</surname> <given-names>Y</given-names></name> <name><surname>Ye</surname> <given-names>Z</given-names></name> <name><surname>Chen</surname> <given-names>S</given-names></name> <name><surname>Mo</surname> <given-names>S</given-names></name> <etal/></person-group>. <article-title>HMGB1 mediates HAdV-7 infection-induced pulmonary inflammation in mice</article-title>. <source>Biochem Biophys Res Commun.</source> (<year>2018</year>) <volume>501</volume>:<fpage>1</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2018.03.145</pub-id><pub-id pub-id-type="pmid">29571731</pub-id></citation></ref>
<ref id="B38">
<label>38.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Paolo</surname> <given-names>NC</given-names></name> <name><surname>Shayakhmetov</surname> <given-names>DM</given-names></name></person-group>. <article-title>Interleukin 1&#x003B1; and the inflammatory process</article-title>. <source>Nat Immunol.</source> (<year>2016</year>) <volume>17</volume>:<fpage>906</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1038/ni.3503</pub-id><pub-id pub-id-type="pmid">27434011</pub-id></citation></ref>
<ref id="B39">
<label>39.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>J</given-names></name> <name><surname>Huang</surname> <given-names>X</given-names></name> <name><surname>Yang</surname> <given-names>Y</given-names></name></person-group>. <article-title>A critical role for type I IFN-dependent NK cell activation in innate immune elimination of adenoviral vectors in vivo</article-title>. <source>Mol Ther.</source> (<year>2008</year>) <volume>16</volume>:<fpage>1300</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/mt.2008.88</pub-id><pub-id pub-id-type="pmid">18443600</pub-id></citation></ref>
<ref id="B40">
<label>40.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>J</given-names></name> <name><surname>Huang</surname> <given-names>X</given-names></name> <name><surname>Yang</surname> <given-names>Y</given-names></name></person-group>. <article-title>NKG2D is required for NK cell activation and function in response to E1-deleted adenovirus</article-title>. <source>J Immunol.</source> (<year>2010</year>) <volume>185</volume>:<fpage>7480</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1002771</pub-id><pub-id pub-id-type="pmid">21076062</pub-id></citation></ref>
<ref id="B41">
<label>41.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lanier</surname> <given-names>LL</given-names></name></person-group>. <article-title>Up on the tightrope: natural killer cell activation and inhibition</article-title>. <source>Nat Immunol.</source> (<year>2008</year>) <volume>9</volume>:<fpage>495</fpage>&#x02013;<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1038/ni1581</pub-id><pub-id pub-id-type="pmid">18425106</pub-id></citation></ref>
<ref id="B42">
<label>42.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waggoner</surname> <given-names>SN</given-names></name> <name><surname>Cornberg</surname> <given-names>M</given-names></name> <name><surname>Selin</surname> <given-names>LK</given-names></name> <name><surname>Welsh</surname> <given-names>RM</given-names></name></person-group>. <article-title>Natural killer cells act as rheostats modulating antiviral T cells</article-title>. <source>Nature.</source> (<year>2011</year>) <volume>481</volume>:<fpage>394</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/nature10624</pub-id><pub-id pub-id-type="pmid">22101430</pub-id></citation></ref>
<ref id="B43">
<label>43.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Narni-Mancinelli</surname> <given-names>E</given-names></name> <name><surname>Jaeger</surname> <given-names>BN</given-names></name> <name><surname>Bernat</surname> <given-names>C</given-names></name> <name><surname>Fenis</surname> <given-names>A</given-names></name> <name><surname>Kung</surname> <given-names>S</given-names></name> <name><surname>De Gassart</surname> <given-names>A</given-names></name> <etal/></person-group>. <article-title>Tuning of natural killer cell reactivity by NKp46 and Helios calibrates T cell responses</article-title>. <source>Science.</source> (<year>2012</year>) <volume>335</volume>:<fpage>344</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1126/science.1215621</pub-id><pub-id pub-id-type="pmid">22267813</pub-id></citation></ref>
<ref id="B44">
<label>44.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ely</surname> <given-names>KH</given-names></name> <name><surname>Matsuoka</surname> <given-names>M</given-names></name> <name><surname>DeBerge</surname> <given-names>MP</given-names></name> <name><surname>Ruby</surname> <given-names>JA</given-names></name> <name><surname>Liu</surname> <given-names>J</given-names></name> <name><surname>Schneider</surname> <given-names>MJ</given-names></name> <etal/></person-group>. <article-title>Tissue-protective effects of NKG2A in immune-mediated clearance of virus infection</article-title>. <source>PLoS ONE.</source> (<year>2014</year>) <volume>9</volume>:<fpage>e108385</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0108385</pub-id><pub-id pub-id-type="pmid">25251060</pub-id></citation></ref>
<ref id="B45">
<label>45.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Isogawa</surname> <given-names>M</given-names></name> <name><surname>Furuichi</surname> <given-names>Y</given-names></name> <name><surname>Chisari</surname> <given-names>FV</given-names></name></person-group>. <article-title>Oscillating CD8(&#x0002B;) T cell effector functions after antigen recognition in the liver</article-title>. <source>Immunity.</source> (<year>2005</year>) <volume>23</volume>:<fpage>53</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2005.05.005</pub-id><pub-id pub-id-type="pmid">16039579</pub-id></citation></ref>
<ref id="B46">
<label>46.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Atasheva</surname> <given-names>S</given-names></name> <name><surname>Yao</surname> <given-names>J</given-names></name> <name><surname>Shayakhmetov</surname> <given-names>DM</given-names></name></person-group>. <article-title>Innate immunity to adenovirus: lessons from mice</article-title>. <source>FEBS Lett.</source> (<year>2019</year>) <volume>593</volume>:<fpage>3461</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1002/1873-3468.13696</pub-id><pub-id pub-id-type="pmid">31769012</pub-id></citation></ref>
<ref id="B47">
<label>47.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fej&#x000E9;r</surname> <given-names>G</given-names></name> <name><surname>Szalay</surname> <given-names>K</given-names></name> <name><surname>Gyory</surname> <given-names>I</given-names></name> <name><surname>Fejes</surname> <given-names>M</given-names></name> <name><surname>K&#x000FA;sz</surname> <given-names>E</given-names></name> <name><surname>Nedieanu</surname> <given-names>S</given-names></name> <etal/></person-group>. <article-title>Adenovirus infection dramatically augments lipopolysaccharide-induced TNF production and sensitizes to lethal shock</article-title>. <source>J Immunol.</source> (<year>2005</year>) <volume>175</volume>:<fpage>1498</fpage>&#x02013;<lpage>506</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.175.3.1498</pub-id><pub-id pub-id-type="pmid">16034087</pub-id></citation></ref>
<ref id="B48">
<label>48.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brundler</surname> <given-names>MA</given-names></name> <name><surname>Rodriguez-Baez</surname> <given-names>N</given-names></name> <name><surname>Jaffe</surname> <given-names>R</given-names></name> <name><surname>Weinberg</surname> <given-names>AG</given-names></name> <name><surname>Rogers</surname> <given-names>BB</given-names></name></person-group>. <article-title>Adenovirus ascending cholangiohepatitis</article-title>. <source>Pediatr Dev Pathol.</source> (<year>2003</year>) <volume>6</volume>:<fpage>156</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s10024-002-0063-4</pub-id><pub-id pub-id-type="pmid">12574911</pub-id></citation></ref>
<ref id="B49">
<label>49.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mortel&#x000E9;</surname> <given-names>KJ</given-names></name> <name><surname>Segatto</surname> <given-names>E</given-names></name> <name><surname>Ros</surname> <given-names>PR</given-names></name></person-group>. <article-title>The infected liver: radiologic-pathologic correlation</article-title>. <source>Radiographics.</source> (<year>2004</year>) <volume>24</volume>:<fpage>937</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1148/rg.244035719</pub-id><pub-id pub-id-type="pmid">15256619</pub-id></citation></ref>
<ref id="B50">
<label>50.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Terasako</surname> <given-names>K</given-names></name> <name><surname>Oshima</surname> <given-names>K</given-names></name> <name><surname>Wada</surname> <given-names>H</given-names></name> <name><surname>Ishihara</surname> <given-names>Y</given-names></name> <name><surname>Kawamura</surname> <given-names>K</given-names></name> <name><surname>Sakamoto</surname> <given-names>K</given-names></name> <etal/></person-group>. <article-title>Fulminant hepatic failure caused by adenovirus infection mimicking peliosis hepatitis on abdominal computed tomography images after allogeneic hematopoietic stem cell transplantation</article-title>. <source>Intern Med.</source> (<year>2012</year>) <volume>51</volume>:<fpage>405</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.2169/internalmedicine.51.6432</pub-id><pub-id pub-id-type="pmid">22333378</pub-id></citation></ref>
<ref id="B51">
<label>51.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>J</given-names></name> <name><surname>Choi</surname> <given-names>EH</given-names></name> <name><surname>Lee</surname> <given-names>HJ</given-names></name></person-group>. <article-title>Comprehensive serotyping and epidemiology of human adenovirus isolated from the respiratory tract of Korean children over 17 consecutive years (1991-2007)</article-title>. <source>J Med Virol.</source> (<year>2010</year>) <volume>82</volume>:<fpage>624</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.21701</pub-id><pub-id pub-id-type="pmid">20166176</pub-id></citation></ref>
<ref id="B52">
<label>52.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rovida</surname> <given-names>F</given-names></name> <name><surname>Percivalle</surname> <given-names>E</given-names></name> <name><surname>Zavattoni</surname> <given-names>M</given-names></name> <name><surname>Torsellini</surname> <given-names>M</given-names></name> <name><surname>Sarasini</surname> <given-names>A</given-names></name> <name><surname>Campanini</surname> <given-names>G</given-names></name> <etal/></person-group>. <article-title>Monoclonal antibodies versus reverse transcription-PCR for detection of respiratory viruses in a patient population with respiratory tract infections admitted to hospital</article-title>. <source>J Med Virol.</source> (<year>2005</year>) <volume>75</volume>:<fpage>336</fpage>&#x02013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.20276</pub-id><pub-id pub-id-type="pmid">15602736</pub-id></citation></ref>
<ref id="B53">
<label>53.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rux</surname> <given-names>JJ</given-names></name> <name><surname>Kuser</surname> <given-names>PR</given-names></name> <name><surname>Burnett</surname> <given-names>RM</given-names></name></person-group>. <article-title>Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods</article-title>. <source>J Virol.</source> (<year>2003</year>) <volume>77</volume>:<fpage>9553</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.77.17.9553-9566.2003</pub-id><pub-id pub-id-type="pmid">12915569</pub-id></citation></ref>
<ref id="B54">
<label>54.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonot</surname> <given-names>S</given-names></name> <name><surname>Ogorzaly</surname> <given-names>L</given-names></name> <name><surname>El Moualij</surname> <given-names>B</given-names></name> <name><surname>Zorzi</surname> <given-names>W</given-names></name> <name><surname>Cauchie</surname> <given-names>HM</given-names></name></person-group>. <article-title>Detection of small amounts of human adenoviruses in stools: comparison of a new immuno real-time PCR assay with classical tools</article-title>. <source>Clin Microbiol Infect.</source> (<year>2014</year>) <volume>20</volume>:<fpage>O1010</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/1469-0691.12768</pub-id><pub-id pub-id-type="pmid">25041100</pub-id></citation></ref>
<ref id="B55">
<label>55.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sujeet</surname> <given-names>K</given-names></name> <name><surname>Vasudev</surname> <given-names>B</given-names></name> <name><surname>Desai</surname> <given-names>P</given-names></name> <name><surname>Bellizzi</surname> <given-names>J</given-names></name> <name><surname>Novoa-Takara</surname> <given-names>L</given-names></name> <name><surname>He</surname> <given-names>C</given-names></name> <etal/></person-group>. <article-title>Acute kidney injury requiring dialysis secondary to adenovirus nephritis in renal transplant recipient</article-title>. <source>Trans Infect Dis.</source> (<year>2011</year>) <volume>13</volume>:<fpage>174</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/j.1399-3062.2010.00577.x</pub-id><pub-id pub-id-type="pmid">20946204</pub-id></citation></ref>
<ref id="B56">
<label>56.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hensley</surname> <given-names>JL</given-names></name> <name><surname>Sifri</surname> <given-names>CD</given-names></name> <name><surname>Cathro</surname> <given-names>HP</given-names></name> <name><surname>Lobo</surname> <given-names>P</given-names></name> <name><surname>Sawyer</surname> <given-names>RG</given-names></name> <name><surname>Brayman</surname> <given-names>KL</given-names></name> <etal/></person-group>. <article-title>Adenoviral graft-nephritis: case report and review of the literature</article-title>. <source>Trans Int.</source> (<year>2009</year>) <volume>22</volume>:<fpage>672</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/j.1432-2277.2009.00838.x</pub-id><pub-id pub-id-type="pmid">19210749</pub-id></citation></ref>
<ref id="B57">
<label>57.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname> <given-names>JY</given-names></name> <name><surname>Lee</surname> <given-names>HJ</given-names></name> <name><surname>Piedra</surname> <given-names>PA</given-names></name> <name><surname>Choi</surname> <given-names>EH</given-names></name> <name><surname>Park</surname> <given-names>KH</given-names></name> <name><surname>Koh</surname> <given-names>YY</given-names></name> <etal/></person-group>. <article-title>Lower respiratory tract infections due to adenovirus in hospitalized Korean children: epidemiology, clinical features, and prognosis</article-title>. <source>Clin Infect Dis.</source> (<year>2001</year>) <volume>32</volume>:<fpage>1423</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1086/320146</pub-id><pub-id pub-id-type="pmid">11317242</pub-id></citation></ref>
<ref id="B58">
<label>58.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moura</surname> <given-names>PO</given-names></name> <name><surname>Roberto</surname> <given-names>AF</given-names></name> <name><surname>Hein</surname> <given-names>N</given-names></name> <name><surname>Baldacci</surname> <given-names>E</given-names></name> <name><surname>Vieira</surname> <given-names>SE</given-names></name> <name><surname>Ejzenberg</surname> <given-names>B</given-names></name> <etal/></person-group>. <article-title>Molecular epidemiology of human adenovirus isolated from children hospitalized with acute respiratory infection in S&#x000E3;o Paulo, Brazil</article-title>. <source>J Med Virol.</source> (<year>2007</year>) <volume>79</volume>:<fpage>174</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.20778</pub-id><pub-id pub-id-type="pmid">17177301</pub-id></citation></ref>
<ref id="B59">
<label>59.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>YJ</given-names></name> <name><surname>Boeckh</surname> <given-names>M</given-names></name> <name><surname>Englund</surname> <given-names>JA</given-names></name></person-group>. <article-title>Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection</article-title>. <source>Semin Respir Crit Care Med.</source> (<year>2007</year>) <volume>28</volume>:<fpage>222</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1055/s-2007-976494</pub-id><pub-id pub-id-type="pmid">17458776</pub-id></citation></ref>
<ref id="B60">
<label>60.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishiko</surname> <given-names>H</given-names></name> <name><surname>Aoki</surname> <given-names>K</given-names></name></person-group>. <article-title>Spread of epidemic keratoconjunctivitis due to a novel serotype of human adenovirus in Japan</article-title>. <source>J Clin Microbiol.</source> (<year>2009</year>) <volume>47</volume>:<fpage>2678</fpage>&#x02013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.r00313-09</pub-id><pub-id pub-id-type="pmid">19644130</pub-id></citation></ref>
<ref id="B61">
<label>61.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yin-Murphy</surname> <given-names>M</given-names></name> <name><surname>Lim</surname> <given-names>KH</given-names></name> <name><surname>Chua</surname> <given-names>PH</given-names></name></person-group>. <article-title>Adenovirus type 11 epidemic conjunctivitis in Singapore</article-title>. <source>Southeast Asian J Trop Med Public Health.</source> (<year>1974</year>) <volume>5</volume>:<fpage>333</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">4372722</pub-id></citation></ref>
<ref id="B62">
<label>62.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kapelushnik</surname> <given-names>J</given-names></name> <name><surname>Or</surname> <given-names>R</given-names></name> <name><surname>Delukina</surname> <given-names>M</given-names></name> <name><surname>Nagler</surname> <given-names>A</given-names></name> <name><surname>Livni</surname> <given-names>N</given-names></name> <name><surname>Engelhard</surname> <given-names>D</given-names></name></person-group>. <article-title>Intravenous ribavirin therapy for adenovirus gastroenteritis after bone marrow transplantation</article-title>. <source>J Pediatr Gastroenterol Nutr.</source> (<year>1995</year>) <volume>21</volume>:<fpage>110</fpage>&#x02013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1097/00005176-199507000-00021</pub-id><pub-id pub-id-type="pmid">8576802</pub-id></citation></ref>
<ref id="B63">
<label>63.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hofland</surname> <given-names>CA</given-names></name> <name><surname>Eron</surname> <given-names>LJ</given-names></name> <name><surname>Washecka</surname> <given-names>RM</given-names></name></person-group>. <article-title>Hemorrhagic adenovirus cystitis after renal transplantation</article-title>. <source>Transplant Proc.</source> (<year>2004</year>) <volume>36</volume>:<fpage>3025</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.transproceed.2004.10.090</pub-id><pub-id pub-id-type="pmid">15686686</pub-id></citation></ref>
<ref id="B64">
<label>64.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yagisawa</surname> <given-names>T</given-names></name> <name><surname>Nakada</surname> <given-names>T</given-names></name> <name><surname>Takahashi</surname> <given-names>K</given-names></name> <name><surname>Toma</surname> <given-names>H</given-names></name> <name><surname>Ota</surname> <given-names>K</given-names></name> <name><surname>Yaguchi</surname> <given-names>H</given-names></name></person-group>. <article-title>Acute hemorrhagic cystitis caused by adenovirus after kidney transplantation</article-title>. <source>Urol Int.</source> (<year>1995</year>) <volume>54</volume>:<fpage>142</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1159/000282708</pub-id><pub-id pub-id-type="pmid">7604455</pub-id></citation></ref>
<ref id="B65">
<label>65.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cimsit</surname> <given-names>B</given-names></name> <name><surname>Tichy</surname> <given-names>EM</given-names></name> <name><surname>Patel</surname> <given-names>SB</given-names></name> <name><surname>Rosencrantz</surname> <given-names>R</given-names></name> <name><surname>Emre</surname> <given-names>S</given-names></name></person-group>. <article-title>Treatment of adenovirus hepatitis with cidofovir in a pediatric liver transplant recipient</article-title>. <source>Pediatr Transplant.</source> (<year>2012</year>) <volume>16</volume>:<fpage>E90</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1111/j.1399-3046.2010.01443.x</pub-id><pub-id pub-id-type="pmid">21226811</pub-id></citation></ref>
<ref id="B66">
<label>66.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mateos</surname> <given-names>ME</given-names></name> <name><surname>L&#x000F3;pez-Laso</surname> <given-names>E</given-names></name> <name><surname>P&#x000E9;rez-Navero</surname> <given-names>JL</given-names></name> <name><surname>Pe&#x000F1;a</surname> <given-names>MJ</given-names></name> <name><surname>Velasco</surname> <given-names>MJ</given-names></name></person-group>. <article-title>Successful response to cidofovir of adenovirus hepatitis during chemotherapy in a child with hepatoblastoma</article-title>. <source>J Pediatr Hematol Oncol.</source> (<year>2012</year>) <volume>34</volume>:<fpage>e298</fpage>&#x02013;<lpage>300</lpage>. <pub-id pub-id-type="doi">10.1097/MPH.0b013e318266ba72</pub-id><pub-id pub-id-type="pmid">22935664</pub-id></citation></ref>
<ref id="B67">
<label>67.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vyas</surname> <given-names>JM</given-names></name> <name><surname>Marasco</surname> <given-names>WA</given-names></name></person-group>. <article-title>Fatal fulminant hepatic failure from adenovirus in allogeneic bone marrow transplant patients</article-title>. <source>Case Rep Infect Dis.</source> (<year>2012</year>) <volume>2012</volume>:<fpage>463569</fpage>. <pub-id pub-id-type="doi">10.1155/2012/463569</pub-id><pub-id pub-id-type="pmid">22928129</pub-id></citation></ref>
<ref id="B68">
<label>68.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kerensky</surname> <given-names>T</given-names></name> <name><surname>Hasan</surname> <given-names>A</given-names></name> <name><surname>Schain</surname> <given-names>D</given-names></name> <name><surname>Trikha</surname> <given-names>G</given-names></name> <name><surname>Liu</surname> <given-names>C</given-names></name> <name><surname>Rand</surname> <given-names>K</given-names></name> <etal/></person-group>. <article-title>Histopathologic resolution of adult liver transplantation adenovirus hepatitis with cidofovir and intravenous immunoglobulin: a case report</article-title>. <source>Transplant Proc.</source> (<year>2013</year>) <volume>45</volume>:<fpage>293</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.transproceed.2012.06.059</pub-id><pub-id pub-id-type="pmid">23267812</pub-id></citation></ref>
<ref id="B69">
<label>69.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>McKillop</surname> <given-names>SJ</given-names></name> <name><surname>Belletrutti</surname> <given-names>MJ</given-names></name> <name><surname>Lee</surname> <given-names>BE</given-names></name> <name><surname>Yap</surname> <given-names>JY</given-names></name> <name><surname>Noga</surname> <given-names>ML</given-names></name> <name><surname>Desai</surname> <given-names>SJ</given-names></name> <etal/></person-group>. <article-title>Adenovirus necrotizing hepatitis complicating atypical teratoid rhabdoid tumor</article-title>. <source>Pediatr Int.</source> (<year>2015</year>) <volume>57</volume>:<fpage>974</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/ped.12674</pub-id><pub-id pub-id-type="pmid">26508178</pub-id></citation></ref>
<ref id="B70">
<label>70.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname> <given-names>RR</given-names></name> <name><surname>Hodinka</surname> <given-names>RL</given-names></name> <name><surname>Kajon</surname> <given-names>AE</given-names></name> <name><surname>Klieger</surname> <given-names>S</given-names></name> <name><surname>Oikonomopoulou</surname> <given-names>Z</given-names></name> <name><surname>Petersen</surname> <given-names>H</given-names></name> <etal/></person-group>. <article-title>A case of adenovirus viremia in a pediatric liver transplant recipient with neutropenia and lymphopenia: who and when should we treat?</article-title> <source>J Pediatric Infect Dis Soc.</source> (<year>2015</year>) <volume>4</volume>:<fpage>e1</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1093/jpids/pit081</pub-id><pub-id pub-id-type="pmid">26407369</pub-id></citation></ref>
<ref id="B71">
<label>71.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matoq</surname> <given-names>A</given-names></name> <name><surname>Salahuddin</surname> <given-names>A</given-names></name></person-group>. <article-title>Acute hepatitis and pancytopenia in healthy infant with adenovirus</article-title>. <source>Case Rep Pediatr.</source> (<year>2016</year>) <volume>2016</volume>:<fpage>8648190</fpage>. <pub-id pub-id-type="doi">10.1155/2016/8648190</pub-id><pub-id pub-id-type="pmid">27340581</pub-id></citation></ref>
<ref id="B72">
<label>72.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haas</surname> <given-names>K</given-names></name> <name><surname>Longacre</surname> <given-names>T</given-names></name> <name><surname>Castillo</surname> <given-names>RO</given-names></name></person-group>. <article-title>Adenovirus hepatic abscess: a novel source of fever of unknown origin in a pediatric liver transplant recipient</article-title>. <source>Dig Dis Sci.</source> (<year>2017</year>) <volume>62</volume>:<fpage>871</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1007/s10620-016-4069-6</pub-id><pub-id pub-id-type="pmid">26856716</pub-id></citation></ref>
<ref id="B73">
<label>73.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buus-Gehrig</surname> <given-names>C</given-names></name> <name><surname>Bochennek</surname> <given-names>K</given-names></name> <name><surname>Hennies</surname> <given-names>MT</given-names></name> <name><surname>Klingebiel</surname> <given-names>T</given-names></name> <name><surname>Groll</surname> <given-names>AH</given-names></name> <name><surname>Lehrnbecher</surname> <given-names>T</given-names></name></person-group>. <article-title>Systemic viral infection in children receiving chemotherapy for acute leukemia</article-title>. <source>Pediatr Blood Cancer.</source> (<year>2020</year>) <volume>67</volume>:<fpage>e28673</fpage>. <pub-id pub-id-type="doi">10.1002/pbc.28673</pub-id><pub-id pub-id-type="pmid">32918533</pub-id></citation></ref>
<ref id="B74">
<label>74.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Onda</surname> <given-names>Y</given-names></name> <name><surname>Kanda</surname> <given-names>J</given-names></name> <name><surname>Sakamoto</surname> <given-names>S</given-names></name> <name><surname>Okada</surname> <given-names>M</given-names></name> <name><surname>Anzai</surname> <given-names>N</given-names></name> <name><surname>Umadome</surname> <given-names>H</given-names></name> <etal/></person-group>. <article-title>Detection of adenovirus hepatitis and acute liver failure in allogeneic hematopoietic stem cell transplant patients</article-title>. <source>Trans Infect Dis.</source> (<year>2020</year>) <volume>23</volume>:<fpage>e13496</fpage>. <pub-id pub-id-type="doi">10.1111/tid.13496</pub-id><pub-id pub-id-type="pmid">33075208</pub-id></citation></ref>
<ref id="B75">
<label>75.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matar</surname> <given-names>AJ</given-names></name> <name><surname>Yoon</surname> <given-names>JC</given-names></name> <name><surname>Mehta</surname> <given-names>AK</given-names></name> <name><surname>Phadke</surname> <given-names>VK</given-names></name> <name><surname>Guarner</surname> <given-names>J</given-names></name> <name><surname>Greer</surname> <given-names>AM</given-names></name> <etal/></person-group>. <article-title>Adenovirus causing hepatic abscess formation and unexplained fever in adult liver transplant recipients</article-title>. <source>Trans Infect Dis.</source> (<year>2021</year>) <volume>23</volume>:<fpage>e13435</fpage>. <pub-id pub-id-type="doi">10.1111/tid.13435</pub-id><pub-id pub-id-type="pmid">32748558</pub-id></citation></ref>
<ref id="B76">
<label>76.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname> <given-names>X</given-names></name> <name><surname>Lu</surname> <given-names>X</given-names></name> <name><surname>Erdman</surname> <given-names>DD</given-names></name> <name><surname>Anderson</surname> <given-names>EJ</given-names></name> <name><surname>Guzman-Cottrill</surname> <given-names>JA</given-names></name> <name><surname>Kletzel</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>Identification of adenoviruses in specimens from high-risk pediatric stem cell transplant recipients and controls</article-title>. <source>J Clin Microbiol.</source> (<year>2008</year>) <volume>46</volume>:<fpage>317</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.01585-07</pub-id><pub-id pub-id-type="pmid">17989198</pub-id></citation></ref>
<ref id="B77">
<label>77.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ED;guez-Mart&#x000ED;nez</surname> <given-names>CE</given-names></name> <name><surname>Rodr&#x000ED;guez</surname> <given-names>DA</given-names></name> <name><surname>Nino</surname> <given-names>G</given-names></name></person-group>. <article-title>Respiratory syncytial virus, adenoviruses, and mixed acute lower respiratory infections in children in a developing country</article-title>. <source>J Med Virol.</source> (<year>2015</year>) <volume>87</volume>:<fpage>774</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.24139</pub-id><pub-id pub-id-type="pmid">25648409</pub-id></citation></ref>
<ref id="B78">
<label>78.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Watcharananan</surname> <given-names>SP</given-names></name> <name><surname>Avery</surname> <given-names>R</given-names></name> <name><surname>Ingsathit</surname> <given-names>A</given-names></name> <name><surname>Malathum</surname> <given-names>K</given-names></name> <name><surname>Chantratita</surname> <given-names>W</given-names></name> <name><surname>Mavichak</surname> <given-names>V</given-names></name> <etal/></person-group>. <article-title>Adenovirus disease after kidney transplantation: course of infection and outcome in relation to blood viral load and immune recovery</article-title>. <source>Am J Trans.</source> (<year>2011</year>) <volume>11</volume>:<fpage>1308</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-6143.2011.03479.x</pub-id><pub-id pub-id-type="pmid">21449944</pub-id></citation></ref>
<ref id="B79">
<label>79.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Mezerville</surname> <given-names>MH</given-names></name> <name><surname>Tellier</surname> <given-names>R</given-names></name> <name><surname>Richardson</surname> <given-names>S</given-names></name> <name><surname>H&#x000E9;bert</surname> <given-names>D</given-names></name> <name><surname>Doyle</surname> <given-names>J</given-names></name> <name><surname>Allen</surname> <given-names>U</given-names></name></person-group>. <article-title>Adenoviral infections in pediatric transplant recipients: a hospital-based study</article-title>. <source>Pediatr Infect Dis J.</source> (<year>2006</year>) <volume>25</volume>:<fpage>815</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1097/01.inf.0000233542.48267.fd</pub-id><pub-id pub-id-type="pmid">16940840</pub-id></citation></ref>
<ref id="B80">
<label>80.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Florescu</surname> <given-names>DF</given-names></name> <name><surname>Islam</surname> <given-names>MK</given-names></name> <name><surname>Mercer</surname> <given-names>DF</given-names></name> <name><surname>Grant</surname> <given-names>W</given-names></name> <name><surname>Langnas</surname> <given-names>AN</given-names></name> <name><surname>Freifeld</surname> <given-names>AG</given-names></name> <etal/></person-group>. <article-title>Adenovirus infections in pediatric small bowel transplant recipients</article-title>. <source>Transplantation.</source> (<year>2010</year>) <volume>90</volume>:<fpage>198</fpage>&#x02013;<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1097/TP.0b013e3181e0de97</pub-id><pub-id pub-id-type="pmid">20467354</pub-id></citation></ref>
<ref id="B81">
<label>81.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hiwarkar</surname> <given-names>P</given-names></name> <name><surname>Amrolia</surname> <given-names>P</given-names></name> <name><surname>Sivaprakasam</surname> <given-names>P</given-names></name> <name><surname>Lum</surname> <given-names>SH</given-names></name> <name><surname>Doss</surname> <given-names>H</given-names></name> <name><surname>O&#x00027;Rafferty</surname> <given-names>C</given-names></name> <etal/></person-group>. <article-title>Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant</article-title>. <source>Blood.</source> (<year>2017</year>) <volume>129</volume>:<fpage>2033</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2016-11-749721</pub-id><pub-id pub-id-type="pmid">28153824</pub-id></citation></ref>
<ref id="B82">
<label>82.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zecca</surname> <given-names>M</given-names></name> <name><surname>Wynn</surname> <given-names>R</given-names></name> <name><surname>Dalle</surname> <given-names>JH</given-names></name> <name><surname>Feuchtinger</surname> <given-names>T</given-names></name> <name><surname>Vainorius</surname> <given-names>E</given-names></name> <name><surname>Brundage</surname> <given-names>TM</given-names></name> <etal/></person-group>. <article-title>Association between adenovirus viral load and mortality in pediatric allo-HCT recipients: the multinational AdVance study</article-title>. <source>Bone Marrow Transplant.</source> (<year>2019</year>) <volume>54</volume>:<fpage>1632</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1038/s41409-019-0483-7</pub-id><pub-id pub-id-type="pmid">30804489</pub-id></citation></ref>
<ref id="B83">
<label>83.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Florescu</surname> <given-names>DF</given-names></name> <name><surname>Pergam</surname> <given-names>SA</given-names></name> <name><surname>Neely</surname> <given-names>MN</given-names></name> <name><surname>Qiu</surname> <given-names>F</given-names></name> <name><surname>Johnston</surname> <given-names>C</given-names></name> <name><surname>Way</surname> <given-names>S</given-names></name> <etal/></person-group>. <article-title>Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients</article-title>. <source>Biol Blood Marrow Transplant.</source> (<year>2012</year>) <volume>18</volume>:<fpage>731</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbmt.2011.09.007</pub-id><pub-id pub-id-type="pmid">21963623</pub-id></citation></ref>
<ref id="B84">
<label>84.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paolino</surname> <given-names>K</given-names></name> <name><surname>Sande</surname> <given-names>J</given-names></name> <name><surname>Perez</surname> <given-names>E</given-names></name> <name><surname>Loechelt</surname> <given-names>B</given-names></name> <name><surname>Jantausch</surname> <given-names>B</given-names></name> <name><surname>Painter</surname> <given-names>W</given-names></name> <etal/></person-group>. <article-title>Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001</article-title>. <source>J Clin Virol.</source> (<year>2011</year>) <volume>50</volume>:<fpage>167</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcv.2010.10.016</pub-id><pub-id pub-id-type="pmid">21094081</pub-id></citation></ref>
<ref id="B85">
<label>85.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morfin</surname> <given-names>F</given-names></name> <name><surname>Dupuis-Girod</surname> <given-names>S</given-names></name> <name><surname>Mundweiler</surname> <given-names>S</given-names></name> <name><surname>Falcon</surname> <given-names>D</given-names></name> <name><surname>Carrington</surname> <given-names>D</given-names></name> <name><surname>Sedlacek</surname> <given-names>P</given-names></name> <etal/></person-group>. <article-title>In vitro susceptibility of adenovirus to antiviral drugs is species-dependent</article-title>. <source>Antivir Ther.</source> (<year>2005</year>) <volume>10</volume>:<fpage>225</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">15865216</pub-id></citation></ref>
<ref id="B86">
<label>86.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname> <given-names>SMC</given-names></name> <name><surname>Michaels</surname> <given-names>MG</given-names></name> <name><surname>Green</surname> <given-names>M</given-names></name></person-group>. <article-title>Adenovirus infection in pediatric transplant recipients: are effective antiviral agents coming our way?</article-title> <source>Curr Opin Organ Transplant.</source> (<year>2018</year>) <volume>23</volume>:<fpage>395</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/MOT.0000000000000542</pub-id><pub-id pub-id-type="pmid">29846196</pub-id></citation></ref>
<ref id="B87">
<label>87.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feuchtinger</surname> <given-names>T</given-names></name> <name><surname>Matthes-Martin</surname> <given-names>S</given-names></name> <name><surname>Richard</surname> <given-names>C</given-names></name> <name><surname>Lion</surname> <given-names>T</given-names></name> <name><surname>Fuhrer</surname> <given-names>M</given-names></name> <name><surname>Hamprecht</surname> <given-names>K</given-names></name> <etal/></person-group>. <article-title>Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation</article-title>. <source>Br J Haematol.</source> (<year>2006</year>) <volume>134</volume>:<fpage>64</fpage>&#x02013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2141.2006.06108.x</pub-id><pub-id pub-id-type="pmid">16803570</pub-id></citation></ref>
<ref id="B88">
<label>88.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chakrabarti</surname> <given-names>S</given-names></name> <name><surname>Mautner</surname> <given-names>V</given-names></name> <name><surname>Osman</surname> <given-names>H</given-names></name> <name><surname>Collingham</surname> <given-names>KE</given-names></name> <name><surname>Fegan</surname> <given-names>CD</given-names></name> <name><surname>Klapper</surname> <given-names>PE</given-names></name> <etal/></person-group>. <article-title>Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery</article-title>. <source>Blood.</source> (<year>2002</year>) <volume>100</volume>:<fpage>1619</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2002-02-0377</pub-id><pub-id pub-id-type="pmid">12176880</pub-id></citation></ref>
<ref id="B89">
<label>89.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gu&#x000E9;rin-El Khourouj</surname> <given-names>V</given-names></name> <name><surname>Dalle</surname> <given-names>JH</given-names></name> <name><surname>P&#x000E9;dron</surname> <given-names>B</given-names></name> <name><surname>Yakouben</surname> <given-names>K</given-names></name> <name><surname>Bensoussan</surname> <given-names>D</given-names></name> <name><surname>Cordeiro</surname> <given-names>DJ</given-names></name> <etal/></person-group>. <article-title>Quantitative and qualitative CD4 T cell immune responses related to adenovirus DNAemia in hematopoietic stem cell transplantation</article-title>. <source>Biol Blood Marrow Transplant.</source> (<year>2011</year>) <volume>17</volume>:<fpage>476</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbmt.2010.09.010</pub-id><pub-id pub-id-type="pmid">20869455</pub-id></citation></ref>
<ref id="B90">
<label>90.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zandvliet</surname> <given-names>ML</given-names></name> <name><surname>Falkenburg</surname> <given-names>JH</given-names></name> <name><surname>van Liempt</surname> <given-names>E</given-names></name> <name><surname>Veltrop-Duits</surname> <given-names>LA</given-names></name> <name><surname>Lankester</surname> <given-names>AC</given-names></name> <name><surname>Kalpoe</surname> <given-names>JS</given-names></name> <etal/></person-group>. <article-title>Combined CD8&#x0002B; and CD4&#x0002B; adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection</article-title>. <source>Haematologica.</source> (<year>2010</year>) <volume>95</volume>:<fpage>1943</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.3324/haematol.2010.022947</pub-id><pub-id pub-id-type="pmid">20562315</pub-id></citation></ref>
<ref id="B91">
<label>91.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feucht</surname> <given-names>J</given-names></name> <name><surname>Opherk</surname> <given-names>K</given-names></name> <name><surname>Lang</surname> <given-names>P</given-names></name> <name><surname>Kayser</surname> <given-names>S</given-names></name> <name><surname>Hartl</surname> <given-names>L</given-names></name> <name><surname>Bethge</surname> <given-names>W</given-names></name> <etal/></person-group>. <article-title>Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT</article-title>. <source>Blood.</source> (<year>2015</year>) <volume>125</volume>:<fpage>1986</fpage>&#x02013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2014-06-573725</pub-id><pub-id pub-id-type="pmid">25617426</pub-id></citation></ref>
<ref id="B92">
<label>92.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Geyeregger</surname> <given-names>R</given-names></name> <name><surname>Freim&#x000FC;ller</surname> <given-names>C</given-names></name> <name><surname>Stemberger</surname> <given-names>J</given-names></name> <name><surname>Artwohl</surname> <given-names>M</given-names></name> <name><surname>Witt</surname> <given-names>V</given-names></name> <name><surname>Lion</surname> <given-names>T</given-names></name> <etal/></person-group>. <article-title>First-in-man clinical results with good manufacturing practice (GMP)-compliant polypeptide-expanded adenovirus-specific T cells after haploidentical hematopoietic stem cell transplantation</article-title>. <source>J Immunother.</source> (<year>2014</year>) <volume>37</volume>:<fpage>245</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/CJI.0000000000000034</pub-id><pub-id pub-id-type="pmid">24714358</pub-id></citation></ref>
<ref id="B93">
<label>93.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Papadopoulou</surname> <given-names>A</given-names></name> <name><surname>Gerdemann</surname> <given-names>U</given-names></name> <name><surname>Katari</surname> <given-names>UL</given-names></name> <name><surname>Tzannou</surname> <given-names>I</given-names></name> <name><surname>Liu</surname> <given-names>H</given-names></name> <name><surname>Martinez</surname> <given-names>C</given-names></name> <etal/></person-group>. <article-title>Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT</article-title>. <source>Sci Transl Med.</source> (<year>2014</year>) <volume>6</volume>:<fpage>242ra83</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.3008825</pub-id><pub-id pub-id-type="pmid">24964991</pub-id></citation></ref>
<ref id="B94">
<label>94.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eiz-Vesper</surname> <given-names>B</given-names></name> <name><surname>Maecker-Kolhoff</surname> <given-names>B</given-names></name> <name><surname>Blasczyk</surname> <given-names>R</given-names></name></person-group>. <article-title>Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry</article-title>. <source>Front Immunol.</source> (<year>2012</year>) <volume>3</volume>:<fpage>410</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2012.00410</pub-id><pub-id pub-id-type="pmid">23372567</pub-id></citation></ref>
<ref id="B95">
<label>95.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qasim</surname> <given-names>W</given-names></name> <name><surname>Derniame</surname> <given-names>S</given-names></name> <name><surname>Gilmour</surname> <given-names>K</given-names></name> <name><surname>Chiesa</surname> <given-names>R</given-names></name> <name><surname>Weber</surname> <given-names>M</given-names></name> <name><surname>Adams</surname> <given-names>S</given-names></name> <etal/></person-group>. <article-title>Third-party virus-specific T cells eradicate adenoviraemia but trigger bystander graft-versus-host disease</article-title>. <source>Br J Haematol.</source> (<year>2011</year>) <volume>154</volume>:<fpage>150</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2141.2011.08579.x</pub-id><pub-id pub-id-type="pmid">21501134</pub-id></citation></ref>
<ref id="B96">
<label>96.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaeuferle</surname> <given-names>T</given-names></name> <name><surname>Krauss</surname> <given-names>R</given-names></name> <name><surname>Blaeschke</surname> <given-names>F</given-names></name> <name><surname>Willier</surname> <given-names>S</given-names></name> <name><surname>Feuchtinger</surname> <given-names>T</given-names></name></person-group>. <article-title>Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation</article-title>. <source>J Hematol Oncol.</source> (<year>2019</year>) <volume>12</volume>:<fpage>13</fpage>. <pub-id pub-id-type="doi">10.1186/s13045-019-0701-1</pub-id><pub-id pub-id-type="pmid">30728058</pub-id></citation></ref>
<ref id="B97">
<label>97.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tzannou</surname> <given-names>I</given-names></name> <name><surname>Papadopoulou</surname> <given-names>A</given-names></name> <name><surname>Naik</surname> <given-names>S</given-names></name> <name><surname>Leung</surname> <given-names>K</given-names></name> <name><surname>Martinez</surname> <given-names>CA</given-names></name> <name><surname>Ramos</surname> <given-names>CA</given-names></name> <etal/></person-group>. <article-title>Off-the-shelf virus-specific T cells to treat BK Virus, human herpesvirus 6, cytomegalovirus, epstein-barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation</article-title>. <source>J Clin Oncol.</source> (<year>2017</year>) <volume>35</volume>:<fpage>3547</fpage>&#x02013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2017.73.0655</pub-id><pub-id pub-id-type="pmid">28783452</pub-id></citation></ref>
<ref id="B98">
<label>98.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lion</surname> <given-names>T</given-names></name> <name><surname>Kosulin</surname> <given-names>K</given-names></name> <name><surname>Landlinger</surname> <given-names>C</given-names></name> <name><surname>Rauch</surname> <given-names>M</given-names></name> <name><surname>Preuner</surname> <given-names>S</given-names></name> <name><surname>Jugovic</surname> <given-names>D</given-names></name> <etal/></person-group>. <article-title>Monitoring of adenovirus load in stool by real-time PCR permits early detection of impending invasive infection in patients after allogeneic stem cell transplantation</article-title>. <source>Leukemia.</source> (<year>2010</year>) <volume>24</volume>:<fpage>706</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1038/leu.2010.4</pub-id><pub-id pub-id-type="pmid">20147979</pub-id></citation></ref>
</ref-list> 
</back>
</article>